EthanOng的个人主页 - 老虎社区

EthanOng

EthanOng

暂无个人介绍

IP属地：未知

28关注

4粉丝

0主题

0勋章

2021-12-17

no nio?

Missed Out on Tesla? Here's What to Buy Now

2021-12-15

When does this end?

Wall Street ends down, investors eye inflation and Omicron

2021-12-15

Save the world!

Pfizer says COVID-19 pill near 90% protective against hospitalization, death

2021-12-14

🤦‍♂️

Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%

2021-12-13

missed the Nvidia train 😢

抱歉，原内容已删除

2021-12-11

Crwd good choice

The Smartest Stocks to Buy With $200 in December

2021-12-11

great news

抱歉，原内容已删除

2021-12-02

Tinder is an app that’s full of scammer accounts. What’s the point?

抱歉，原内容已删除

2021-11-30

Get ARCT. Soon to be the vaccine that rulesthem all. 😬

Stocks open lower as investors assess omicron concerns

2021-11-30

What about Arcturus? $ARCT

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

2021-11-29

How will it match up to rivals?

抱歉，原内容已删除

2021-11-25

just keep buying!

Will Palantir Be a Trillion-Dollar Stock by 2040?

2021-04-14

PLTR ALL THE WAY!

抱歉，原内容已删除

2021-04-14

BTWN for the win!

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573003064152790","uuid":"3573003064152790","gmtCreate":1609920274563,"gmtModify":1618413916442,"name":"EthanOng","pinyin":"ethanong","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":4,"headSize":28,"tweetSize":14,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.83%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":690771395,"gmtCreate":1639714582019,"gmtModify":1639714582103,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"no nio?","listText":"no nio?","text":"no nio?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690771395","repostId":"1115262079","repostType":2,"repost":{"id":"1115262079","kind":"news","pubTimestamp":1639712748,"share":"https://www.laohu8.com/m/news/1115262079?lang=&edition=full","pubTime":"2021-12-17 11:45","market":"us","language":"en","title":"Missed Out on Tesla? Here's What to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1115262079","media":"Motley Fool","summary":"The growing use of electric vehicles will benefit several players.","content":"<p>In the last two years,<b>Tesla</b>&nbsp;stock has surged more than 1,000%. Investors who missed investing in Tesla two years back could be disheartened. Yet it is worth noting that it is difficult to foresee stocks that can generate Tesla-like returns. The best approach is to invest in companies that you believe can perform well in the long haul. Stocks of such quality companies should generate market-beating returns if you hold them long enough.</p>\n<p>Let's look at three&nbsp;electric vehicle (EV) stocks&nbsp;that have the potential to generate outsize returns in five years, or more.</p>\n<p><b>Lucid Group</b></p>\n<p>There is a plethora of electric vehicle stocks to choose from right now. Of these,<b>Lucid Group</b>(NASDAQ:LCID)&nbsp;looks promising. There are several reasons to like Lucid Group. Users like the cars' features and designs, and within a short time, Lucid has succeeded in establishing itself as a luxury electric car brand.</p>\n<p>The company not only boasts leading-edge EV technology, but also has&nbsp;solid growth plans. Though Lucid started as a luxury car maker, it has plans to launch EV models for the mass market in the coming years. With one of the most&nbsp;efficient EV technologies, Lucid can potentially generate recurring revenue by licensing its technology to other car companies.&nbsp;The stock will be&nbsp;included&nbsp;in the&nbsp;<b>Nasdaq-100</b>&nbsp;index on Dec. 20.</p>\n<p>On the risk side, Lucid is still to prove that it can deliver cars profitably. Investors should also keep an eye on the progress of a&nbsp;recent Securities and Exchange Commission (SEC) investigation&nbsp;relating to its merger with Churchill Capital Corp. IV.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d0630d0ca5a26df1b8900958ace25117\" tg-width=\"2000\" tg-height=\"1327\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: LUCID GROUP.</span></p>\n<p><b>BYD</b></p>\n<p>Founded in 1995,<b>BYD</b>(OTC:BYDDY)(OTC:BYDD.F)&nbsp;entered the automobile business in 2003. Apart from automobiles, BYD manufactures mobile handset components, rechargeable batteries, and solar products.<b>Berkshire Hathaway</b>(NYSE:BRK.A)(NYSE:BRK.B)&nbsp;holds a nearly 8% stake in BYD.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cb8e45b9379833fe0a8f6a1d482857a5\" tg-width=\"2000\" tg-height=\"1161\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>BYD started as an internal combustion engine vehicle manufacturer. Yet, sensing the broader trend, it has quickly shifted to making electric vehicles. In November, more than 90% of BYD's vehicle deliveries were fully electric or plug-in hybrids. Sales of BYD's fully electric models rose 153% year over year in November.</p>\n<p>The company has captured roughly 18% of China's EV market. A leading position in the fast-growing, huge potential Chinese EV market places BYD well for long-term growth.</p>\n<p>BYD stock trades at an&nbsp;attractive valuation&nbsp;compared to several top EV stocks right now. All of the above makes this&nbsp;Warren Buffett stock&nbsp;attractive.</p>\n<p><b>QuantumScape</b></p>\n<p>Batteries are a key component of electric vehicles. All leading auto and battery companies are focused on making batteries more efficient, which will help enhance an EV's range.<b>QuantumScape</b>(NYSE:QS), which went public in November 2020, is a battery start-up working on the next-generation battery technology.</p>\n<p>Currently, lithium-ion batteries are used in electric vehicles. QuantumScape is developing lithium-metal solid-state batteries, using a proprietary ceramic separator. The company believes that its batteries will offer greater energy density, longer life, and faster charging than lithium-ion batteries currently in use.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7c6ead4e5b8f1aaa74490058d439dbfa\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>QuantumScape has the backing of leading automaker&nbsp;<b>Volkswagen</b>(OTC:VWAGY), which has invested $300 million into the battery technology company so far. The two companies have formed a joint venture for a production capacity of 21 gigawatt-hours per year. In September, QuantumScape entered an agreement for 10 megawatt-hours of batteries with another top ten automaker by revenue. The company didn't disclose the name of the automaker. All the above lend credibility to QuantumScape's plans. If successful, QuantumScape's batteries could see immense demand from automakers worldwide.</p>\n<p>QuantumScape believes it is progressing as per its plan to start commercial production in 2024. That's a long time and the company's batteries are not yet developed. Investors should&nbsp;bear the risks in mind&nbsp;before deciding to invest in QuantumScape stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Out on Tesla? Here's What to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Out on Tesla? Here's What to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/16/missed-out-on-tesla-heres-what-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the last two years,Tesla stock has surged more than 1,000%. Investors who missed investing in Tesla two years back could be disheartened. Yet it is worth noting that it is difficult to foresee ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/16/missed-out-on-tesla-heres-what-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01211":"比亚迪股份","LCID":"Lucid Group Inc","QS":"Quantumscape Corp.","BYDDY":"比亚迪ADR"},"source_url":"https://www.fool.com/investing/2021/12/16/missed-out-on-tesla-heres-what-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115262079","content_text":"In the last two years,Tesla stock has surged more than 1,000%. Investors who missed investing in Tesla two years back could be disheartened. Yet it is worth noting that it is difficult to foresee stocks that can generate Tesla-like returns. The best approach is to invest in companies that you believe can perform well in the long haul. Stocks of such quality companies should generate market-beating returns if you hold them long enough.\nLet's look at three electric vehicle (EV) stocks that have the potential to generate outsize returns in five years, or more.\nLucid Group\nThere is a plethora of electric vehicle stocks to choose from right now. Of these,Lucid Group(NASDAQ:LCID) looks promising. There are several reasons to like Lucid Group. Users like the cars' features and designs, and within a short time, Lucid has succeeded in establishing itself as a luxury electric car brand.\nThe company not only boasts leading-edge EV technology, but also has solid growth plans. Though Lucid started as a luxury car maker, it has plans to launch EV models for the mass market in the coming years. With one of the most efficient EV technologies, Lucid can potentially generate recurring revenue by licensing its technology to other car companies. The stock will be included in the Nasdaq-100 index on Dec. 20.\nOn the risk side, Lucid is still to prove that it can deliver cars profitably. Investors should also keep an eye on the progress of a recent Securities and Exchange Commission (SEC) investigation relating to its merger with Churchill Capital Corp. IV.\nIMAGE SOURCE: LUCID GROUP.\nBYD\nFounded in 1995,BYD(OTC:BYDDY)(OTC:BYDD.F) entered the automobile business in 2003. Apart from automobiles, BYD manufactures mobile handset components, rechargeable batteries, and solar products.Berkshire Hathaway(NYSE:BRK.A)(NYSE:BRK.B) holds a nearly 8% stake in BYD.\nIMAGE SOURCE: GETTY IMAGES.\nBYD started as an internal combustion engine vehicle manufacturer. Yet, sensing the broader trend, it has quickly shifted to making electric vehicles. In November, more than 90% of BYD's vehicle deliveries were fully electric or plug-in hybrids. Sales of BYD's fully electric models rose 153% year over year in November.\nThe company has captured roughly 18% of China's EV market. A leading position in the fast-growing, huge potential Chinese EV market places BYD well for long-term growth.\nBYD stock trades at an attractive valuation compared to several top EV stocks right now. All of the above makes this Warren Buffett stock attractive.\nQuantumScape\nBatteries are a key component of electric vehicles. All leading auto and battery companies are focused on making batteries more efficient, which will help enhance an EV's range.QuantumScape(NYSE:QS), which went public in November 2020, is a battery start-up working on the next-generation battery technology.\nCurrently, lithium-ion batteries are used in electric vehicles. QuantumScape is developing lithium-metal solid-state batteries, using a proprietary ceramic separator. The company believes that its batteries will offer greater energy density, longer life, and faster charging than lithium-ion batteries currently in use.\nIMAGE SOURCE: GETTY IMAGES.\nQuantumScape has the backing of leading automaker Volkswagen(OTC:VWAGY), which has invested $300 million into the battery technology company so far. The two companies have formed a joint venture for a production capacity of 21 gigawatt-hours per year. In September, QuantumScape entered an agreement for 10 megawatt-hours of batteries with another top ten automaker by revenue. The company didn't disclose the name of the automaker. All the above lend credibility to QuantumScape's plans. If successful, QuantumScape's batteries could see immense demand from automakers worldwide.\nQuantumScape believes it is progressing as per its plan to start commercial production in 2024. That's a long time and the company's batteries are not yet developed. Investors should bear the risks in mind before deciding to invest in QuantumScape stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1046,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607885507,"gmtCreate":1639525286798,"gmtModify":1639525286861,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"When does this end?","listText":"When does this end?","text":"When does this end?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607885507","repostId":"2191784951","repostType":4,"repost":{"id":"2191784951","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639522244,"share":"https://www.laohu8.com/m/news/2191784951?lang=&edition=full","pubTime":"2021-12-15 06:50","market":"us","language":"en","title":"Wall Street ends down, investors eye inflation and Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2191784951","media":"Reuters","summary":"* Fed policy decision awaited on Wednesday\n* November PPI logs highest rise since 2010\n* Tech leads ","content":"<p>* Fed policy decision awaited on Wednesday</p>\n<p>* November PPI logs highest rise since 2010</p>\n<p>* Tech leads declines, financials rally</p>\n<p>* Indexes: Dow -0.30%, S&amp;P 500 -0.75%, Nasdaq -1.14%</p>\n<p>Dec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.</p>\n<p>The fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&amp;P 500 index hit an all-time closing high late last week.</p>\n<p>Declines were led by megacap tech-related stocks, with <a href=\"https://laohu8.com/S/CRM\">Salesforce</a>.com, Microsoft Corp, <a href=\"https://laohu8.com/S/ADBE\">Adobe</a> and Alphabet Inc pulling down the S&amp;P 500 and Nasdaq.</p>\n<p>Apple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.</p>\n<p>The Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&amp;P 500 lost 0.75% to 4,634.09.</p>\n<p>The Nasdaq Composite dropped 1.14% to 15,237.64.</p>\n<p>Data from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.</p>\n<p>About two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.</p>\n<p>\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.</p>\n<p>Berkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&amp;P 500 from falling further.</p>\n<p>Many investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.</p>\n<p>\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6ea56cda700f032a3421aa26db08524\" tg-width=\"596\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Inflation</span></p>\n<p>Beyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"</p>\n<p>Pfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.</p>\n<p>Volume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down, investors eye inflation and Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down, investors eye inflation and Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-15 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Fed policy decision awaited on Wednesday</p>\n<p>* November PPI logs highest rise since 2010</p>\n<p>* Tech leads declines, financials rally</p>\n<p>* Indexes: Dow -0.30%, S&amp;P 500 -0.75%, Nasdaq -1.14%</p>\n<p>Dec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.</p>\n<p>The fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&amp;P 500 index hit an all-time closing high late last week.</p>\n<p>Declines were led by megacap tech-related stocks, with <a href=\"https://laohu8.com/S/CRM\">Salesforce</a>.com, Microsoft Corp, <a href=\"https://laohu8.com/S/ADBE\">Adobe</a> and Alphabet Inc pulling down the S&amp;P 500 and Nasdaq.</p>\n<p>Apple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.</p>\n<p>The Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&amp;P 500 lost 0.75% to 4,634.09.</p>\n<p>The Nasdaq Composite dropped 1.14% to 15,237.64.</p>\n<p>Data from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.</p>\n<p>About two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.</p>\n<p>\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.</p>\n<p>Berkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&amp;P 500 from falling further.</p>\n<p>Many investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.</p>\n<p>\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6ea56cda700f032a3421aa26db08524\" tg-width=\"596\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Inflation</span></p>\n<p>Beyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"</p>\n<p>Pfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.</p>\n<p>Volume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SSO":"两倍做多标普500ETF","BK4559":"巴菲特持仓",".DJI":"道琼斯","BK4550":"红杉资本持仓","SPXU":"三倍做空标普500ETF","BK4079":"房地产服务","SPY":"标普500ETF","OEF":"标普100指数ETF-iShares","BK4504":"桥水持仓",".IXIC":"NASDAQ Composite","SDS":"两倍做空标普500ETF",".SPX":"S&P 500 Index","AAPL":"苹果","BK4539":"次新股","COMP":"Compass, Inc.","OEX":"标普100","BK4534":"瑞士信贷持仓","SH":"标普500反向ETF","IVV":"标普500指数ETF","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191784951","content_text":"* Fed policy decision awaited on Wednesday\n* November PPI logs highest rise since 2010\n* Tech leads declines, financials rally\n* Indexes: Dow -0.30%, S&P 500 -0.75%, Nasdaq -1.14%\nDec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.\nThe fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&P 500 index hit an all-time closing high late last week.\nDeclines were led by megacap tech-related stocks, with Salesforce.com, Microsoft Corp, Adobe and Alphabet Inc pulling down the S&P 500 and Nasdaq.\nApple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.\nThe Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&P 500 lost 0.75% to 4,634.09.\nThe Nasdaq Composite dropped 1.14% to 15,237.64.\nData from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.\nAbout two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.\n\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"\nTen of the 11 major S&P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.\nBerkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&P 500 from falling further.\nMany investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.\n\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.\nA Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.\nInflation\nBeyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"\nPfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.\nThe S&P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.\nVolume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607885969,"gmtCreate":1639525247866,"gmtModify":1639525247866,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Save the world!","listText":"Save the world!","text":"Save the world!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607885969","repostId":"2191937155","repostType":4,"repost":{"id":"2191937155","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639521474,"share":"https://www.laohu8.com/m/news/2191937155?lang=&edition=full","pubTime":"2021-12-15 06:37","market":"us","language":"en","title":"Pfizer says COVID-19 pill near 90% protective against hospitalization, death","url":"https://stock-news.laohu8.com/highlight/detail?id=2191937155","media":"Reuters","summary":"NEW YORK, Dec 14 (Reuters) - Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% ","content":"<p>NEW YORK, Dec 14 (Reuters) - Pfizer Inc&nbsp;on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.</p>\n<p>The U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Data from its final analysis of the trial disclosed on Tuesday includes an additional 1,000 people.</p>\n<p>Nobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients.</p>\n<p>The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.</p>\n<p>\"It's a stunning outcome,\" Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.</p>\n<p>\"We're talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically,\" Dolsten said.</p>\n<p>Pfizer also released early data from a second study suggesting that the treatment reduced hospitalizations by around 70% in a smaller trial of standard-risk adults, including some higher-risk vaccinated people.</p>\n<p>Pfizer said those results showed a positive trend, but were not statistically significant. They are following the results and plan to release data from the final 20% of participants in the 1,100-patient trial. The trial did not show that the drug alleviated symptoms of COVID-19 in that population.</p>\n<p>Dolsten said he expects authorization for use in high-risk individuals from the U.S. Food and Drug Administration and other regulatory agencies soon. He does not believe an FDA advisory panel meeting will be needed.</p>\n<p>\"We're in very advanced regulatory dialogues with both Europe and the UK, and we have dialogues with most of the major regulatory agencies globally,\" Dolsten said.</p>\n<p><b>'VERY EXCITING RESULTS'</b></p>\n<p>Pfizer submitted data to the FDA last month, asking for emergency use authorization (EUA) of the drug.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/04e1175e6a0c8ba936538fabc8038071\" tg-width=\"960\" tg-height=\"640\" width=\"100%\" height=\"auto\"><span>Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS</span></p>\n<p>\"These are very exciting results,\" said Dr. Paul Sax, a professor at Harvard Medical School.</p>\n<p>Sax said the FDA should try to accelerate the authorization process as much as possible, noting there are very limited treatment options for high-risk people outside of the hospital.</p>\n<p>There are currently no oral antiviral treatments for COVID-9 authorized in the United States.</p>\n<p>Analysts on average forecast 2022 revenue of more than $24 billion from the pill, which would more than make up for any decline in vaccine sales after 2021.</p>\n<p>Rival Merck &amp; Co&nbsp;has asked for an EUA for its antiviral pill molnupiravir. But that drug only reduced hospitalizations and deaths in its clinical trial of high-risk patients by around 30%.</p>\n<p>Some scientists have also raised safety concerns about the potential for birth defects from the Merck drug, as well as worries that it could cause the virus to mutate.</p>\n<p>Pfizer's treatment works differently. It is part of a class of drugs called protease inhibitors currently used to treat HIV, hepatitis C and other viruses.</p>\n<p>Recent laboratory testing showed that activity against the protease of the Omicron variant is as \"good as basically any SARS-COV-2 variant of concern,\" Dolsten said.</p>\n<p>The company has said it can have 180,000 treatment courses ready to ship this year and plans to produce at least 80 million more in 2022.</p>\n<p>Dolsten said Pfizer is looking to expand that output further as new variants, like the newly-discovered Omicron, could push the need for antivirals substantially higher. Current vaccines appear to be less effective at preventing infection with Omicron.</p>\n<p>Pfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech , has agreed to allow generic manufacturers to supply versions of the drug to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). However, Dolsten said that for next year he expects the drug will be mainly produced by Pfizer.</p>\n<p>The MPP told Reuters in a statement, that it will be \"well into next year\" before pills produced by generic manufacturers under its licenses will be ready for use.</p>\n<p>The U.S. government has already secured 10 million courses of the Pfizer treatment for $5.29 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer says COVID-19 pill near 90% protective against hospitalization, death</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer says COVID-19 pill near 90% protective against hospitalization, death\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-15 06:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Dec 14 (Reuters) - Pfizer Inc&nbsp;on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.</p>\n<p>The U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Data from its final analysis of the trial disclosed on Tuesday includes an additional 1,000 people.</p>\n<p>Nobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients.</p>\n<p>The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.</p>\n<p>\"It's a stunning outcome,\" Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.</p>\n<p>\"We're talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically,\" Dolsten said.</p>\n<p>Pfizer also released early data from a second study suggesting that the treatment reduced hospitalizations by around 70% in a smaller trial of standard-risk adults, including some higher-risk vaccinated people.</p>\n<p>Pfizer said those results showed a positive trend, but were not statistically significant. They are following the results and plan to release data from the final 20% of participants in the 1,100-patient trial. The trial did not show that the drug alleviated symptoms of COVID-19 in that population.</p>\n<p>Dolsten said he expects authorization for use in high-risk individuals from the U.S. Food and Drug Administration and other regulatory agencies soon. He does not believe an FDA advisory panel meeting will be needed.</p>\n<p>\"We're in very advanced regulatory dialogues with both Europe and the UK, and we have dialogues with most of the major regulatory agencies globally,\" Dolsten said.</p>\n<p><b>'VERY EXCITING RESULTS'</b></p>\n<p>Pfizer submitted data to the FDA last month, asking for emergency use authorization (EUA) of the drug.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/04e1175e6a0c8ba936538fabc8038071\" tg-width=\"960\" tg-height=\"640\" width=\"100%\" height=\"auto\"><span>Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS</span></p>\n<p>\"These are very exciting results,\" said Dr. Paul Sax, a professor at Harvard Medical School.</p>\n<p>Sax said the FDA should try to accelerate the authorization process as much as possible, noting there are very limited treatment options for high-risk people outside of the hospital.</p>\n<p>There are currently no oral antiviral treatments for COVID-9 authorized in the United States.</p>\n<p>Analysts on average forecast 2022 revenue of more than $24 billion from the pill, which would more than make up for any decline in vaccine sales after 2021.</p>\n<p>Rival Merck &amp; Co&nbsp;has asked for an EUA for its antiviral pill molnupiravir. But that drug only reduced hospitalizations and deaths in its clinical trial of high-risk patients by around 30%.</p>\n<p>Some scientists have also raised safety concerns about the potential for birth defects from the Merck drug, as well as worries that it could cause the virus to mutate.</p>\n<p>Pfizer's treatment works differently. It is part of a class of drugs called protease inhibitors currently used to treat HIV, hepatitis C and other viruses.</p>\n<p>Recent laboratory testing showed that activity against the protease of the Omicron variant is as \"good as basically any SARS-COV-2 variant of concern,\" Dolsten said.</p>\n<p>The company has said it can have 180,000 treatment courses ready to ship this year and plans to produce at least 80 million more in 2022.</p>\n<p>Dolsten said Pfizer is looking to expand that output further as new variants, like the newly-discovered Omicron, could push the need for antivirals substantially higher. Current vaccines appear to be less effective at preventing infection with Omicron.</p>\n<p>Pfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech , has agreed to allow generic manufacturers to supply versions of the drug to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). However, Dolsten said that for next year he expects the drug will be mainly produced by Pfizer.</p>\n<p>The MPP told Reuters in a statement, that it will be \"well into next year\" before pills produced by generic manufacturers under its licenses will be ready for use.</p>\n<p>The U.S. government has already secured 10 million courses of the Pfizer treatment for $5.29 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","PFE":"辉瑞","BK4550":"红杉资本持仓","BK4007":"制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191937155","content_text":"NEW YORK, Dec 14 (Reuters) - Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.\nThe U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Data from its final analysis of the trial disclosed on Tuesday includes an additional 1,000 people.\nNobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients.\nThe Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.\n\"It's a stunning outcome,\" Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.\n\"We're talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically,\" Dolsten said.\nPfizer also released early data from a second study suggesting that the treatment reduced hospitalizations by around 70% in a smaller trial of standard-risk adults, including some higher-risk vaccinated people.\nPfizer said those results showed a positive trend, but were not statistically significant. They are following the results and plan to release data from the final 20% of participants in the 1,100-patient trial. The trial did not show that the drug alleviated symptoms of COVID-19 in that population.\nDolsten said he expects authorization for use in high-risk individuals from the U.S. Food and Drug Administration and other regulatory agencies soon. He does not believe an FDA advisory panel meeting will be needed.\n\"We're in very advanced regulatory dialogues with both Europe and the UK, and we have dialogues with most of the major regulatory agencies globally,\" Dolsten said.\n'VERY EXCITING RESULTS'\nPfizer submitted data to the FDA last month, asking for emergency use authorization (EUA) of the drug.\nPaxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS\n\"These are very exciting results,\" said Dr. Paul Sax, a professor at Harvard Medical School.\nSax said the FDA should try to accelerate the authorization process as much as possible, noting there are very limited treatment options for high-risk people outside of the hospital.\nThere are currently no oral antiviral treatments for COVID-9 authorized in the United States.\nAnalysts on average forecast 2022 revenue of more than $24 billion from the pill, which would more than make up for any decline in vaccine sales after 2021.\nRival Merck & Co has asked for an EUA for its antiviral pill molnupiravir. But that drug only reduced hospitalizations and deaths in its clinical trial of high-risk patients by around 30%.\nSome scientists have also raised safety concerns about the potential for birth defects from the Merck drug, as well as worries that it could cause the virus to mutate.\nPfizer's treatment works differently. It is part of a class of drugs called protease inhibitors currently used to treat HIV, hepatitis C and other viruses.\nRecent laboratory testing showed that activity against the protease of the Omicron variant is as \"good as basically any SARS-COV-2 variant of concern,\" Dolsten said.\nThe company has said it can have 180,000 treatment courses ready to ship this year and plans to produce at least 80 million more in 2022.\nDolsten said Pfizer is looking to expand that output further as new variants, like the newly-discovered Omicron, could push the need for antivirals substantially higher. Current vaccines appear to be less effective at preventing infection with Omicron.\nPfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech , has agreed to allow generic manufacturers to supply versions of the drug to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). However, Dolsten said that for next year he expects the drug will be mainly produced by Pfizer.\nThe MPP told Reuters in a statement, that it will be \"well into next year\" before pills produced by generic manufacturers under its licenses will be ready for use.\nThe U.S. government has already secured 10 million courses of the Pfizer treatment for $5.29 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1072,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604411980,"gmtCreate":1639438187676,"gmtModify":1639438272899,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"🤦‍♂️","listText":"🤦‍♂️","text":"🤦‍♂️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604411980","repostId":"1180743412","repostType":4,"repost":{"id":"1180743412","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639408228,"share":"https://www.laohu8.com/m/news/1180743412?lang=&edition=full","pubTime":"2021-12-13 23:10","market":"us","language":"en","title":"Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180743412","media":"Tiger Newspress","summary":"Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.","content":"<p>Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.<img src=\"https://static.tigerbbs.com/8c494e3841010c65a07f05aaacf0d443\" tg-width=\"772\" tg-height=\"573\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 23:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.<img src=\"https://static.tigerbbs.com/8c494e3841010c65a07f05aaacf0d443\" tg-width=\"772\" tg-height=\"573\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PHUN":"Phunware, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180743412","content_text":"Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604362023,"gmtCreate":1639351900923,"gmtModify":1639351900994,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"missed the Nvidia train 😢","listText":"missed the Nvidia train 😢","text":"missed the Nvidia train 😢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604362023","repostId":"2190992671","repostType":4,"isVote":1,"tweetType":1,"viewCount":1380,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3583318222987864","authorId":"3583318222987864","name":"TheMilkyWay","avatar":"https://static.tigerbbs.com/190d59bcbcc876e15543cbd430d8c1f2","crmLevel":3,"crmLevelSwitch":0,"idStr":"3583318222987864","authorIdStr":"3583318222987864"},"content":"Have not missed yet, the semi stocks are pulling back now. Maybe will have chance to jump onboard soon? Anyway so much upside potential, good to hold longterm.","text":"Have not missed yet, the semi stocks are pulling back now. Maybe will have chance to jump onboard soon? Anyway so much upside potential, good to hold longterm.","html":"Have not missed yet, the semi stocks are pulling back now. Maybe will have chance to jump onboard soon? Anyway so much upside potential, good to hold longterm."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605629851,"gmtCreate":1639154390585,"gmtModify":1639154390585,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Crwd good choice","listText":"Crwd good choice","text":"Crwd good choice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605629851","repostId":"2190296066","repostType":4,"repost":{"id":"2190296066","kind":"highlight","pubTimestamp":1639150220,"share":"https://www.laohu8.com/m/news/2190296066?lang=&edition=full","pubTime":"2021-12-10 23:30","market":"us","language":"en","title":"The Smartest Stocks to Buy With $200 in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2190296066","media":"Motley Fool","summary":"A small investment can go a long way with this mix of growth, income, and value stocks.","content":"<p>Despite volatility rearing its head over the past couple of weeks, it's been another stellar year for the stock market. Through Dec. 6, the benchmark <b>S&amp;P 500</b> has gained 22% on a year-to-date basis. That essentially doubles up the average annual total return, including dividends, of the S&amp;P 500 since 1980 (about 11%).</p>\n<p>But just because the broader market is up big, it doesn't mean there aren't still bargains to be found. For patient investors who lean on time as their ally, there are plenty of stocks that can make them richer.</p>\n<p>Best of all, you don't need a mountain of money to build wealth on Wall Street. With most brokerages eliminating minimum deposit requirements and trading commissions, any amount of money -- even $200 -- can be the right amount to grow your portfolio.</p>\n<p>If you have $200 ready to invest, the following are some of the smartest stocks you can buy in December.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5876cf8596571681f0d3218da4f74c8c\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>CrowdStrike Holdings</h2>\n<p>One of the smartest buys investors can make is scooping up shares of premier cybersecurity stock <b>CrowdStrike Holdings</b> (NASDAQ:CRWD).</p>\n<p>Cybersecurity may not be the fastest-growing trend, but there's arguably not a safer double-digit growth opportunity through the midpoint of the decade. Since hackers and robots don't take time off just because the U.S. economy or stock market hit a rough patch, businesses are increasingly turning to third-party providers to secure their data and that of their clients.</p>\n<p>What makes CrowdStrike special is its cloud-native Falcon security platform. Falcon relies on artificial intelligence to grow smarter over time and is currently overseeing about 1 trillion events <i>per day</i>. As a cloud-based platform, Falcon is often better at recognizing and responding to threats than on-premises solutions. While CrowdStrike's solutions aren't the cheapest on a nominal basis, the long-term reward of data protection makes Falcon a more cost-effective platform for businesses.</p>\n<p>The proof is in the pudding that clients are thrilled with CrowdStrike's suite of services. The total number of subscribers has skyrocketed from 450 to almost 14,700 in less than five years, with 68% of its clients purchasing four or more cloud-module subscriptions, as of Sept. 30. The latter is up from under 10% less than five years ago. The company's customer retention rate has also hovered around 98% for two years running.</p>\n<p>CrowdStrike's stock isn't inexpensive using standard fundamental metrics. However, a valuation premium is certainly warranted with its subscription gross margin already at its long-term target this early in its expansion.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/626f702dc64e03a6186f9231d5b698b4\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>AT&amp;T</h2>\n<p>Keep in mind that it's not just growth stocks that are begging to be bought. Value and income plays like telecom stock <b>AT&amp;T</b> (NYSE:T) represent a smart way to put $200 to work right now.</p>\n<p>To state the obvious, AT&amp;T's high-growth heyday is long gone. But just because the company has matured, it doesn't mean there aren't organic growth opportunities on its doorstep.</p>\n<p>For instance, AT&amp;T should benefit nicely from the ongoing rollout of 5G wireless infrastructure. Although upgrading its infrastructure won't be cheap, the investment will pay off handsomely. That's because it's been a decade since wireless download speeds were meaningfully improved. With 5G becoming widely available, consumers and businesses are liable to undertake a multiyear device upgrade cycle to take advantage of a faster network. Since the bulk of AT&amp;T's wireless margins derive from data consumption, 5G should provide a healthy shot of organic growth through at least 2025.</p>\n<p>AT&amp;T is also in the process of spinning off its content arm, WarnerMedia, and combining it with <b>Discovery</b>&nbsp;to create a new media powerhouse. The new company should have over 85 million streaming subscribers, a more diverse content library, and it'll be able to cut its operating costs by over $3 billion a year.</p>\n<p>At an estimated 7 times forecasted earnings per share this year, and a high-yield dividend to boot, AT&amp;T is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the smartest value and income plays to buy now.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/5aacd35062c7935f82d018ba2d593ab6\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Exelixis</h2>\n<p>Another genius purchase investors can make in December with $200 is biotech stock <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Exelixis has had a bit of a rough year, with its shares down close to 20%. The cancer-focused drug developer disappointed Wall Street in late June when it unveiled interim analysis data from the late-stage Cosmic-312 study in patients with previously untreated liver cancer. The company's lead drug, Cabometyx, was paired with atezolizumab (better known by its brand name, Tecentriq) in this study. While progression-free survival data hit the mark, the company noted it was unlikely that overall survival data would show a statistically significant improvement versus Nexavar.</p>\n<p>Though this was undoubtedly disappointing, as first-line hepatocellular carcinoma (HCC) is an indication that could use more-effective treatments, the downside Exelixis' shares have seen since this data release looks to be an overreaction.</p>\n<p>Even assuming the Food and Drug Administration doesn't grant this combo treatment approval in first-line HCC -- the company plans to file a supplemental new drug application in Q1 2022 -- Cabometyx is in line for well over $1 billion in annual revenue from first- and second-line kidney cancer indications and more advanced cases of HCC.</p>\n<p>Furthermore, Cabometyx is being examined in close to six dozen clinical trials. Some failures are expected. But if even a handful of these studies result in label expansion opportunities, Cabometyx could surpass $2 billion in annual sales.</p>\n<p>With Exelixis sitting on a whopping $1.8 billion in cash, cash equivalents, and restricted cash equivalents and investments (this is about 35% of its market cap), and the company's price-earnings-to-growth ratio well below 1, it has all the hallmarks of a screaming buy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b13f98298635a74f4491a99bf47eeded\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/WBA\">Walgreens Boots Alliance</a></h2>\n<p>A final smart stock investors can buy with $200 in December is pharmacy chain <b>Walgreens Boots Alliance</b> (NASDAQ:WBA). Similar to AT&amp;T, this is another value/income play that's not getting the love it deserves.</p>\n<p>Normally, healthcare stocks aren't adversely affected by economic downturns. Since we can't control when we get sick or what ailment(s) we develop, there's always demand for drugs, devices, and healthcare services. But during the pandemic, Walgreens wasn't as lucky. Reduced foot traffic hurt demand for front-end sales and clinic revenue.</p>\n<p>That's the bad news. The good news is Walgreens is incredibly inexpensive following the worst of the pandemic, and it's already well into a multipoint turnaround plan designed to increase margins and boost its organic growth rate.</p>\n<p>Initially, management anticipated reducing annual operating expenses by $2 billion as of the end of fiscal 2022. But cost-cutting activity has been far better than expected. Walgreens achieved more than $2 billion in annual cost reductions, and it did so by the end of fiscal 2021.</p>\n<p>However, it's not cost-cutting that should have investors excited. Rather, it's the company's investments. For example, Walgreens has spared no expense when it comes to its investments in digitization. Placing greater emphasis on direct-to-consumer sales should result in sustainable double-digit online revenue growth.</p>\n<p>Walgreens has also partnered with VillageMD to open more than 600 full-service clinics in over 30 U.S. markets by 2025. These co-located clinics will be physician-staffed and should play a key role in funneling local residents to the company's higher-margin pharmacy.</p>\n<p>At less than 10 times Wall Street's forecasted earnings per share for fiscal 2022, Walgreens Boots Alliance is a steal.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $200 in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $200 in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/10/the-smartest-stocks-to-buy-with-200-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Despite volatility rearing its head over the past couple of weeks, it's been another stellar year for the stock market. Through Dec. 6, the benchmark S&P 500 has gained 22% on a year-to-date basis. ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/10/the-smartest-stocks-to-buy-with-200-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"WBA":"沃尔格林联合博姿","EXEL":"伊克力西斯","BK4507":"流媒体概念","BK4534":"瑞士信贷持仓","BK4097":"系统软件","BK4128":"药品零售","BK4550":"红杉资本持仓","BK4139":"生物科技","BK4006":"钢铁","BK4560":"网络安全概念","BK4528":"SaaS概念","BK4115":"综合电信业务","CRWD":"CrowdStrike Holdings, Inc.","BK4532":"文艺复兴科技持仓","BK4515":"5G概念","BK4551":"寇图资本持仓","HCC":"Warrior Met Coal LLC","T":"美国电话电报"},"source_url":"https://www.fool.com/investing/2021/12/10/the-smartest-stocks-to-buy-with-200-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190296066","content_text":"Despite volatility rearing its head over the past couple of weeks, it's been another stellar year for the stock market. Through Dec. 6, the benchmark S&P 500 has gained 22% on a year-to-date basis. That essentially doubles up the average annual total return, including dividends, of the S&P 500 since 1980 (about 11%).\nBut just because the broader market is up big, it doesn't mean there aren't still bargains to be found. For patient investors who lean on time as their ally, there are plenty of stocks that can make them richer.\nBest of all, you don't need a mountain of money to build wealth on Wall Street. With most brokerages eliminating minimum deposit requirements and trading commissions, any amount of money -- even $200 -- can be the right amount to grow your portfolio.\nIf you have $200 ready to invest, the following are some of the smartest stocks you can buy in December.\nImage source: Getty Images.\nCrowdStrike Holdings\nOne of the smartest buys investors can make is scooping up shares of premier cybersecurity stock CrowdStrike Holdings (NASDAQ:CRWD).\nCybersecurity may not be the fastest-growing trend, but there's arguably not a safer double-digit growth opportunity through the midpoint of the decade. Since hackers and robots don't take time off just because the U.S. economy or stock market hit a rough patch, businesses are increasingly turning to third-party providers to secure their data and that of their clients.\nWhat makes CrowdStrike special is its cloud-native Falcon security platform. Falcon relies on artificial intelligence to grow smarter over time and is currently overseeing about 1 trillion events per day. As a cloud-based platform, Falcon is often better at recognizing and responding to threats than on-premises solutions. While CrowdStrike's solutions aren't the cheapest on a nominal basis, the long-term reward of data protection makes Falcon a more cost-effective platform for businesses.\nThe proof is in the pudding that clients are thrilled with CrowdStrike's suite of services. The total number of subscribers has skyrocketed from 450 to almost 14,700 in less than five years, with 68% of its clients purchasing four or more cloud-module subscriptions, as of Sept. 30. The latter is up from under 10% less than five years ago. The company's customer retention rate has also hovered around 98% for two years running.\nCrowdStrike's stock isn't inexpensive using standard fundamental metrics. However, a valuation premium is certainly warranted with its subscription gross margin already at its long-term target this early in its expansion.\nImage source: Getty Images.\nAT&T\nKeep in mind that it's not just growth stocks that are begging to be bought. Value and income plays like telecom stock AT&T (NYSE:T) represent a smart way to put $200 to work right now.\nTo state the obvious, AT&T's high-growth heyday is long gone. But just because the company has matured, it doesn't mean there aren't organic growth opportunities on its doorstep.\nFor instance, AT&T should benefit nicely from the ongoing rollout of 5G wireless infrastructure. Although upgrading its infrastructure won't be cheap, the investment will pay off handsomely. That's because it's been a decade since wireless download speeds were meaningfully improved. With 5G becoming widely available, consumers and businesses are liable to undertake a multiyear device upgrade cycle to take advantage of a faster network. Since the bulk of AT&T's wireless margins derive from data consumption, 5G should provide a healthy shot of organic growth through at least 2025.\nAT&T is also in the process of spinning off its content arm, WarnerMedia, and combining it with Discovery to create a new media powerhouse. The new company should have over 85 million streaming subscribers, a more diverse content library, and it'll be able to cut its operating costs by over $3 billion a year.\nAt an estimated 7 times forecasted earnings per share this year, and a high-yield dividend to boot, AT&T is one of the smartest value and income plays to buy now.\nImage source: Getty Images.\nExelixis\nAnother genius purchase investors can make in December with $200 is biotech stock Exelixis (NASDAQ:EXEL).\nExelixis has had a bit of a rough year, with its shares down close to 20%. The cancer-focused drug developer disappointed Wall Street in late June when it unveiled interim analysis data from the late-stage Cosmic-312 study in patients with previously untreated liver cancer. The company's lead drug, Cabometyx, was paired with atezolizumab (better known by its brand name, Tecentriq) in this study. While progression-free survival data hit the mark, the company noted it was unlikely that overall survival data would show a statistically significant improvement versus Nexavar.\nThough this was undoubtedly disappointing, as first-line hepatocellular carcinoma (HCC) is an indication that could use more-effective treatments, the downside Exelixis' shares have seen since this data release looks to be an overreaction.\nEven assuming the Food and Drug Administration doesn't grant this combo treatment approval in first-line HCC -- the company plans to file a supplemental new drug application in Q1 2022 -- Cabometyx is in line for well over $1 billion in annual revenue from first- and second-line kidney cancer indications and more advanced cases of HCC.\nFurthermore, Cabometyx is being examined in close to six dozen clinical trials. Some failures are expected. But if even a handful of these studies result in label expansion opportunities, Cabometyx could surpass $2 billion in annual sales.\nWith Exelixis sitting on a whopping $1.8 billion in cash, cash equivalents, and restricted cash equivalents and investments (this is about 35% of its market cap), and the company's price-earnings-to-growth ratio well below 1, it has all the hallmarks of a screaming buy.\nImage source: Getty Images.\nWalgreens Boots Alliance\nA final smart stock investors can buy with $200 in December is pharmacy chain Walgreens Boots Alliance (NASDAQ:WBA). Similar to AT&T, this is another value/income play that's not getting the love it deserves.\nNormally, healthcare stocks aren't adversely affected by economic downturns. Since we can't control when we get sick or what ailment(s) we develop, there's always demand for drugs, devices, and healthcare services. But during the pandemic, Walgreens wasn't as lucky. Reduced foot traffic hurt demand for front-end sales and clinic revenue.\nThat's the bad news. The good news is Walgreens is incredibly inexpensive following the worst of the pandemic, and it's already well into a multipoint turnaround plan designed to increase margins and boost its organic growth rate.\nInitially, management anticipated reducing annual operating expenses by $2 billion as of the end of fiscal 2022. But cost-cutting activity has been far better than expected. Walgreens achieved more than $2 billion in annual cost reductions, and it did so by the end of fiscal 2021.\nHowever, it's not cost-cutting that should have investors excited. Rather, it's the company's investments. For example, Walgreens has spared no expense when it comes to its investments in digitization. Placing greater emphasis on direct-to-consumer sales should result in sustainable double-digit online revenue growth.\nWalgreens has also partnered with VillageMD to open more than 600 full-service clinics in over 30 U.S. markets by 2025. These co-located clinics will be physician-staffed and should play a key role in funneling local residents to the company's higher-margin pharmacy.\nAt less than 10 times Wall Street's forecasted earnings per share for fiscal 2022, Walgreens Boots Alliance is a steal.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605620426,"gmtCreate":1639154224060,"gmtModify":1639154224060,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"great news","listText":"great news","text":"great news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/605620426","repostId":"1199826178","repostType":4,"isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603216892,"gmtCreate":1638412417840,"gmtModify":1638413977936,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Tinder is an app that’s full of scammer accounts. What’s the point?","listText":"Tinder is an app that’s full of scammer accounts. What’s the point?","text":"Tinder is an app that’s full of scammer accounts. What’s the point?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603216892","repostId":"2188564633","repostType":4,"isVote":1,"tweetType":1,"viewCount":1017,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609239848,"gmtCreate":1638284771792,"gmtModify":1638284771792,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Get ARCT. Soon to be the vaccine that rulesthem all. 😬","listText":"Get ARCT. Soon to be the vaccine that rulesthem all. 😬","text":"Get ARCT. Soon to be the vaccine that rulesthem all. 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609239848","repostId":"1167187587","repostType":4,"repost":{"id":"1167187587","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638282732,"share":"https://www.laohu8.com/m/news/1167187587?lang=&edition=full","pubTime":"2021-11-30 22:32","market":"us","language":"en","title":"Stocks open lower as investors assess omicron concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1167187587","media":"Tiger Newspress","summary":"Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks ","content":"<p>Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks associated with the new omicron Covid variant.</p>\n<p>The Dow Jones Industrial Average dropped about 290 points, or 0.8%. The S&amp;P 500 shed 0.64%. The technology-heavy Nasdaq Composite shed about 0.4%. The small-cap benchmark Russell 2000 dropped 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/078050fb74fa44676c309ee766ee815d\" tg-width=\"1080\" tg-height=\"472\" referrerpolicy=\"no-referrer\"></p>\n<p>Tuesday's reversal came after&nbsp;Moderna&nbsp;CEO Stephane Bancel told the Financial Times that he&nbsp;expects existing vaccines to be less effective&nbsp;against the new variant. The CEO told the paper there could be a \"material drop\" in the current vaccines' effectiveness against this variant. Bancel told CNBC on Monday that it could take&nbsp;months to develop and ship an omicron-specific vaccine. Moderna was down nearly 4%.</p>\n<p>Separately,Regeneron&nbsp;said its antibody treatment may have reduced effectiveness against omicron. Regeneron shares lost about 1%.</p>\n<p>Travel shares, which led Friday's drop and then gained on Monday, were taking hits once again Tuesday.Expedia Group&nbsp;fell 2%,Norwegian Cruise Line Holdings&nbsp;and&nbsp;American Airlines&nbsp;&nbsp;shares&nbsp;tumbled about&nbsp;2%.</p>\n<p>Bucking the broader market's trend, stay-at-home stock Netflix rose 1.4% and Tesla gained 1.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks open lower as investors assess omicron concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks open lower as investors assess omicron concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-30 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks associated with the new omicron Covid variant.</p>\n<p>The Dow Jones Industrial Average dropped about 290 points, or 0.8%. The S&amp;P 500 shed 0.64%. The technology-heavy Nasdaq Composite shed about 0.4%. The small-cap benchmark Russell 2000 dropped 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/078050fb74fa44676c309ee766ee815d\" tg-width=\"1080\" tg-height=\"472\" referrerpolicy=\"no-referrer\"></p>\n<p>Tuesday's reversal came after&nbsp;Moderna&nbsp;CEO Stephane Bancel told the Financial Times that he&nbsp;expects existing vaccines to be less effective&nbsp;against the new variant. The CEO told the paper there could be a \"material drop\" in the current vaccines' effectiveness against this variant. Bancel told CNBC on Monday that it could take&nbsp;months to develop and ship an omicron-specific vaccine. Moderna was down nearly 4%.</p>\n<p>Separately,Regeneron&nbsp;said its antibody treatment may have reduced effectiveness against omicron. Regeneron shares lost about 1%.</p>\n<p>Travel shares, which led Friday's drop and then gained on Monday, were taking hits once again Tuesday.Expedia Group&nbsp;fell 2%,Norwegian Cruise Line Holdings&nbsp;and&nbsp;American Airlines&nbsp;&nbsp;shares&nbsp;tumbled about&nbsp;2%.</p>\n<p>Bucking the broader market's trend, stay-at-home stock Netflix rose 1.4% and Tesla gained 1.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167187587","content_text":"Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks associated with the new omicron Covid variant.\nThe Dow Jones Industrial Average dropped about 290 points, or 0.8%. The S&P 500 shed 0.64%. The technology-heavy Nasdaq Composite shed about 0.4%. The small-cap benchmark Russell 2000 dropped 0.7%.\n\nTuesday's reversal came after Moderna CEO Stephane Bancel told the Financial Times that he expects existing vaccines to be less effective against the new variant. The CEO told the paper there could be a \"material drop\" in the current vaccines' effectiveness against this variant. Bancel told CNBC on Monday that it could take months to develop and ship an omicron-specific vaccine. Moderna was down nearly 4%.\nSeparately,Regeneron said its antibody treatment may have reduced effectiveness against omicron. Regeneron shares lost about 1%.\nTravel shares, which led Friday's drop and then gained on Monday, were taking hits once again Tuesday.Expedia Group fell 2%,Norwegian Cruise Line Holdings and American Airlines  shares tumbled about 2%.\nBucking the broader market's trend, stay-at-home stock Netflix rose 1.4% and Tesla gained 1.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609296965,"gmtCreate":1638284483570,"gmtModify":1638284483570,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"What about Arcturus? $ARCT","listText":"What about Arcturus? $ARCT","text":"What about Arcturus? $ARCT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609296965","repostId":"1190156196","repostType":2,"repost":{"id":"1190156196","kind":"news","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","JNJ":"强生","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600844252,"gmtCreate":1638142736784,"gmtModify":1638142736784,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"How will it match up to rivals?","listText":"How will it match up to rivals?","text":"How will it match up to rivals?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600844252","repostId":"1103197941","repostType":4,"isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877900584,"gmtCreate":1637852589386,"gmtModify":1637852589386,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"just keep buying!","listText":"just keep buying!","text":"just keep buying!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877900584","repostId":"2186916023","repostType":2,"repost":{"id":"2186916023","kind":"highlight","pubTimestamp":1637848500,"share":"https://www.laohu8.com/m/news/2186916023?lang=&edition=full","pubTime":"2021-11-25 21:55","market":"us","language":"en","title":"Will Palantir Be a Trillion-Dollar Stock by 2040?","url":"https://stock-news.laohu8.com/highlight/detail?id=2186916023","media":"Motley Fool","summary":"The data-mining firm has a slim chance of eventually joining the 12-zero club.","content":"<p><b>Palantir Technologies</b> (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed more government and enterprise contracts.</p>\n<p>The bears pointed out that Palantir was too heavily dependent on government clients, its enterprise business faced too many competitors, it was deeply unprofitable, and its stock was too expensive.</p>\n<p>Palantir's stock price has experienced some wild swings over the past year, but it has still more than doubled since its first trade at $10 per share.</p>\n<p>Today, Palantir is valued at $41.3 billion, or 27 times this year's sales. The bears will argue that the high price-to-sales (P/S) ratio will limit its upside, especially as rising interest rates and inflation make many high-growth tech stocks less attractive.</p>\n<p>But let's look beyond the near-term noise and see if Palantir can still generate big multibagger gains, or even become a trillion-dollar stock, over the next two decades.</p>\n<h2>How fast is Palantir growing?</h2>\n<p>Palantir expects to grow its revenue by at least 30% annually between fiscal 2021 and 2025. That forecast implies its revenue will rise from its target of $1.5 billion this year to at least $4.3 billion in 2025.</p>\n<p>The company expects that growth to be driven by its new and expanded contracts with government agencies, as well as the growth of its Foundry platform for large commercial customers. The accelerating growth of its commercial business over the past year, which notably outpaced the growth of its government business last quarter, supports that thesis.</p>\n<h2>Palantir's path toward a trillion-dollar market cap</h2>\n<p>Palantir hasn't provided any longer-term targets beyond 2025. But based on the growth trajectory of other big data companies like <b><a href=\"https://laohu8.com/S/CRM\">Salesforce</a> </b>(NYSE:CRM), its annual revenue increase could potentially decelerate and stabilize at about 20% over the following 10 years.</p>\n<p>If it hits its target for 2025, then continues to grow its revenue at an average rate of 20% over the following 10 years, it could generate nearly $27 billion in revenue in 2035.</p>\n<p>If Palantir's revenue growth then slows down to 15% per year, which would be more comparable to <b>Microsoft</b>'s (NASDAQ:MSFT) current rate, it could generate over $53 billion in revenue in 2040.</p>\n<p>Assuming the company is still valued at over 20 times sales, its market cap could surpass $1 trillion. But most tech giants that grow their revenue 15% to 25% annually aren't valued at more than 20 times sales.</p>\n<p>Microsoft, which is expected to generate 17% sales growth this year, trades at 13 times that estimate. Salesforce, which is expected to generate 24% sales growth this year, trades at just 11 times this year's sales.</p>\n<p>Therefore, Palantir's market cap could potentially hit $1 trillion by 2040, but it seems highly unlikely. Instead, it will likely be closer to $500 billion (which would still be a 12-bagger gain from its current valuation) if its stock is trading at a more reasonable P/S ratio of 10.</p>\n<h2>Look beyond the market caps</h2>\n<p>Instead of focusing on Palantir's path toward joining the 12-zero club, investors should focus on its ability to generate sustainable growth.</p>\n<p>The company has gained a firm foothold with the U.S. government, but it still faces competition from internally developed systems. Immigration and Customs Enforcement (ICE), for example, has been developing its own platform to replace Palantir's Falcon. If other agencies follow ICE's lead, the company's dream of becoming the \"default operating system for data across the U.S. government\" could abruptly end.</p>\n<p>Palantir is making solid progress in the commercial market, but its Foundry platform still faces plenty of indirect competitors like <b>C3.ai</b>, <b>Salesforce</b>'s Tableau, and Glue from <b>Amazon</b> Web Services.</p>\n<p>The company likely believes its reputation as a battle-hardened platform for the U.S. military and government agencies will attract more enterprise customers. But there's no guarantee that this appeal will last for decades or fend off newer, hungrier, and more disruptive players in the data-mining market.</p>\n<h2>Is Palantir's stock still worth buying?</h2>\n<p>I still believe Palantir's stock is a promising long-term investment on the secular growth of the data-mining and analytics market. However, there's a lot of growth already baked into the stock, and its high valuations could limit its near-term and long-term potential. Palantir probably won't hit a trillion-dollar valuation within the next two decades, but it could still outperform the market and generate impressive multibagger gains.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Palantir Be a Trillion-Dollar Stock by 2040?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Palantir Be a Trillion-Dollar Stock by 2040?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 21:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186916023","content_text":"Palantir Technologies (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed more government and enterprise contracts.\nThe bears pointed out that Palantir was too heavily dependent on government clients, its enterprise business faced too many competitors, it was deeply unprofitable, and its stock was too expensive.\nPalantir's stock price has experienced some wild swings over the past year, but it has still more than doubled since its first trade at $10 per share.\nToday, Palantir is valued at $41.3 billion, or 27 times this year's sales. The bears will argue that the high price-to-sales (P/S) ratio will limit its upside, especially as rising interest rates and inflation make many high-growth tech stocks less attractive.\nBut let's look beyond the near-term noise and see if Palantir can still generate big multibagger gains, or even become a trillion-dollar stock, over the next two decades.\nHow fast is Palantir growing?\nPalantir expects to grow its revenue by at least 30% annually between fiscal 2021 and 2025. That forecast implies its revenue will rise from its target of $1.5 billion this year to at least $4.3 billion in 2025.\nThe company expects that growth to be driven by its new and expanded contracts with government agencies, as well as the growth of its Foundry platform for large commercial customers. The accelerating growth of its commercial business over the past year, which notably outpaced the growth of its government business last quarter, supports that thesis.\nPalantir's path toward a trillion-dollar market cap\nPalantir hasn't provided any longer-term targets beyond 2025. But based on the growth trajectory of other big data companies like Salesforce (NYSE:CRM), its annual revenue increase could potentially decelerate and stabilize at about 20% over the following 10 years.\nIf it hits its target for 2025, then continues to grow its revenue at an average rate of 20% over the following 10 years, it could generate nearly $27 billion in revenue in 2035.\nIf Palantir's revenue growth then slows down to 15% per year, which would be more comparable to Microsoft's (NASDAQ:MSFT) current rate, it could generate over $53 billion in revenue in 2040.\nAssuming the company is still valued at over 20 times sales, its market cap could surpass $1 trillion. But most tech giants that grow their revenue 15% to 25% annually aren't valued at more than 20 times sales.\nMicrosoft, which is expected to generate 17% sales growth this year, trades at 13 times that estimate. Salesforce, which is expected to generate 24% sales growth this year, trades at just 11 times this year's sales.\nTherefore, Palantir's market cap could potentially hit $1 trillion by 2040, but it seems highly unlikely. Instead, it will likely be closer to $500 billion (which would still be a 12-bagger gain from its current valuation) if its stock is trading at a more reasonable P/S ratio of 10.\nLook beyond the market caps\nInstead of focusing on Palantir's path toward joining the 12-zero club, investors should focus on its ability to generate sustainable growth.\nThe company has gained a firm foothold with the U.S. government, but it still faces competition from internally developed systems. Immigration and Customs Enforcement (ICE), for example, has been developing its own platform to replace Palantir's Falcon. If other agencies follow ICE's lead, the company's dream of becoming the \"default operating system for data across the U.S. government\" could abruptly end.\nPalantir is making solid progress in the commercial market, but its Foundry platform still faces plenty of indirect competitors like C3.ai, Salesforce's Tableau, and Glue from Amazon Web Services.\nThe company likely believes its reputation as a battle-hardened platform for the U.S. military and government agencies will attract more enterprise customers. But there's no guarantee that this appeal will last for decades or fend off newer, hungrier, and more disruptive players in the data-mining market.\nIs Palantir's stock still worth buying?\nI still believe Palantir's stock is a promising long-term investment on the secular growth of the data-mining and analytics market. However, there's a lot of growth already baked into the stock, and its high valuations could limit its near-term and long-term potential. Palantir probably won't hit a trillion-dollar valuation within the next two decades, but it could still outperform the market and generate impressive multibagger gains.","news_type":1},"isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":344225693,"gmtCreate":1618411319812,"gmtModify":1634293115193,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"PLTR ALL THE WAY!","listText":"PLTR ALL THE WAY!","text":"PLTR ALL THE WAY!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/344225693","repostId":"1193747033","repostType":4,"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":344228861,"gmtCreate":1618411197453,"gmtModify":1634293117285,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"BTWN for the win!","listText":"BTWN for the win!","text":"BTWN for the win!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/344228861","repostId":"1106153811","repostType":4,"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":690771395,"gmtCreate":1639714582019,"gmtModify":1639714582103,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"no nio?","listText":"no nio?","text":"no nio?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/690771395","repostId":"1115262079","repostType":2,"repost":{"id":"1115262079","kind":"news","pubTimestamp":1639712748,"share":"https://www.laohu8.com/m/news/1115262079?lang=&edition=full","pubTime":"2021-12-17 11:45","market":"us","language":"en","title":"Missed Out on Tesla? Here's What to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=1115262079","media":"Motley Fool","summary":"The growing use of electric vehicles will benefit several players.","content":"<p>In the last two years,<b>Tesla</b>&nbsp;stock has surged more than 1,000%. Investors who missed investing in Tesla two years back could be disheartened. Yet it is worth noting that it is difficult to foresee stocks that can generate Tesla-like returns. The best approach is to invest in companies that you believe can perform well in the long haul. Stocks of such quality companies should generate market-beating returns if you hold them long enough.</p>\n<p>Let's look at three&nbsp;electric vehicle (EV) stocks&nbsp;that have the potential to generate outsize returns in five years, or more.</p>\n<p><b>Lucid Group</b></p>\n<p>There is a plethora of electric vehicle stocks to choose from right now. Of these,<b>Lucid Group</b>(NASDAQ:LCID)&nbsp;looks promising. There are several reasons to like Lucid Group. Users like the cars' features and designs, and within a short time, Lucid has succeeded in establishing itself as a luxury electric car brand.</p>\n<p>The company not only boasts leading-edge EV technology, but also has&nbsp;solid growth plans. Though Lucid started as a luxury car maker, it has plans to launch EV models for the mass market in the coming years. With one of the most&nbsp;efficient EV technologies, Lucid can potentially generate recurring revenue by licensing its technology to other car companies.&nbsp;The stock will be&nbsp;included&nbsp;in the&nbsp;<b>Nasdaq-100</b>&nbsp;index on Dec. 20.</p>\n<p>On the risk side, Lucid is still to prove that it can deliver cars profitably. Investors should also keep an eye on the progress of a&nbsp;recent Securities and Exchange Commission (SEC) investigation&nbsp;relating to its merger with Churchill Capital Corp. IV.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/d0630d0ca5a26df1b8900958ace25117\" tg-width=\"2000\" tg-height=\"1327\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: LUCID GROUP.</span></p>\n<p><b>BYD</b></p>\n<p>Founded in 1995,<b>BYD</b>(OTC:BYDDY)(OTC:BYDD.F)&nbsp;entered the automobile business in 2003. Apart from automobiles, BYD manufactures mobile handset components, rechargeable batteries, and solar products.<b>Berkshire Hathaway</b>(NYSE:BRK.A)(NYSE:BRK.B)&nbsp;holds a nearly 8% stake in BYD.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/cb8e45b9379833fe0a8f6a1d482857a5\" tg-width=\"2000\" tg-height=\"1161\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>BYD started as an internal combustion engine vehicle manufacturer. Yet, sensing the broader trend, it has quickly shifted to making electric vehicles. In November, more than 90% of BYD's vehicle deliveries were fully electric or plug-in hybrids. Sales of BYD's fully electric models rose 153% year over year in November.</p>\n<p>The company has captured roughly 18% of China's EV market. A leading position in the fast-growing, huge potential Chinese EV market places BYD well for long-term growth.</p>\n<p>BYD stock trades at an&nbsp;attractive valuation&nbsp;compared to several top EV stocks right now. All of the above makes this&nbsp;Warren Buffett stock&nbsp;attractive.</p>\n<p><b>QuantumScape</b></p>\n<p>Batteries are a key component of electric vehicles. All leading auto and battery companies are focused on making batteries more efficient, which will help enhance an EV's range.<b>QuantumScape</b>(NYSE:QS), which went public in November 2020, is a battery start-up working on the next-generation battery technology.</p>\n<p>Currently, lithium-ion batteries are used in electric vehicles. QuantumScape is developing lithium-metal solid-state batteries, using a proprietary ceramic separator. The company believes that its batteries will offer greater energy density, longer life, and faster charging than lithium-ion batteries currently in use.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7c6ead4e5b8f1aaa74490058d439dbfa\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<p>QuantumScape has the backing of leading automaker&nbsp;<b>Volkswagen</b>(OTC:VWAGY), which has invested $300 million into the battery technology company so far. The two companies have formed a joint venture for a production capacity of 21 gigawatt-hours per year. In September, QuantumScape entered an agreement for 10 megawatt-hours of batteries with another top ten automaker by revenue. The company didn't disclose the name of the automaker. All the above lend credibility to QuantumScape's plans. If successful, QuantumScape's batteries could see immense demand from automakers worldwide.</p>\n<p>QuantumScape believes it is progressing as per its plan to start commercial production in 2024. That's a long time and the company's batteries are not yet developed. Investors should&nbsp;bear the risks in mind&nbsp;before deciding to invest in QuantumScape stock.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Missed Out on Tesla? Here's What to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMissed Out on Tesla? Here's What to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 11:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/16/missed-out-on-tesla-heres-what-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the last two years,Tesla stock has surged more than 1,000%. Investors who missed investing in Tesla two years back could be disheartened. Yet it is worth noting that it is difficult to foresee ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/16/missed-out-on-tesla-heres-what-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01211":"比亚迪股份","LCID":"Lucid Group Inc","QS":"Quantumscape Corp.","BYDDY":"比亚迪ADR"},"source_url":"https://www.fool.com/investing/2021/12/16/missed-out-on-tesla-heres-what-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115262079","content_text":"In the last two years,Tesla stock has surged more than 1,000%. Investors who missed investing in Tesla two years back could be disheartened. Yet it is worth noting that it is difficult to foresee stocks that can generate Tesla-like returns. The best approach is to invest in companies that you believe can perform well in the long haul. Stocks of such quality companies should generate market-beating returns if you hold them long enough.\nLet's look at three electric vehicle (EV) stocks that have the potential to generate outsize returns in five years, or more.\nLucid Group\nThere is a plethora of electric vehicle stocks to choose from right now. Of these,Lucid Group(NASDAQ:LCID) looks promising. There are several reasons to like Lucid Group. Users like the cars' features and designs, and within a short time, Lucid has succeeded in establishing itself as a luxury electric car brand.\nThe company not only boasts leading-edge EV technology, but also has solid growth plans. Though Lucid started as a luxury car maker, it has plans to launch EV models for the mass market in the coming years. With one of the most efficient EV technologies, Lucid can potentially generate recurring revenue by licensing its technology to other car companies. The stock will be included in the Nasdaq-100 index on Dec. 20.\nOn the risk side, Lucid is still to prove that it can deliver cars profitably. Investors should also keep an eye on the progress of a recent Securities and Exchange Commission (SEC) investigation relating to its merger with Churchill Capital Corp. IV.\nIMAGE SOURCE: LUCID GROUP.\nBYD\nFounded in 1995,BYD(OTC:BYDDY)(OTC:BYDD.F) entered the automobile business in 2003. Apart from automobiles, BYD manufactures mobile handset components, rechargeable batteries, and solar products.Berkshire Hathaway(NYSE:BRK.A)(NYSE:BRK.B) holds a nearly 8% stake in BYD.\nIMAGE SOURCE: GETTY IMAGES.\nBYD started as an internal combustion engine vehicle manufacturer. Yet, sensing the broader trend, it has quickly shifted to making electric vehicles. In November, more than 90% of BYD's vehicle deliveries were fully electric or plug-in hybrids. Sales of BYD's fully electric models rose 153% year over year in November.\nThe company has captured roughly 18% of China's EV market. A leading position in the fast-growing, huge potential Chinese EV market places BYD well for long-term growth.\nBYD stock trades at an attractive valuation compared to several top EV stocks right now. All of the above makes this Warren Buffett stock attractive.\nQuantumScape\nBatteries are a key component of electric vehicles. All leading auto and battery companies are focused on making batteries more efficient, which will help enhance an EV's range.QuantumScape(NYSE:QS), which went public in November 2020, is a battery start-up working on the next-generation battery technology.\nCurrently, lithium-ion batteries are used in electric vehicles. QuantumScape is developing lithium-metal solid-state batteries, using a proprietary ceramic separator. The company believes that its batteries will offer greater energy density, longer life, and faster charging than lithium-ion batteries currently in use.\nIMAGE SOURCE: GETTY IMAGES.\nQuantumScape has the backing of leading automaker Volkswagen(OTC:VWAGY), which has invested $300 million into the battery technology company so far. The two companies have formed a joint venture for a production capacity of 21 gigawatt-hours per year. In September, QuantumScape entered an agreement for 10 megawatt-hours of batteries with another top ten automaker by revenue. The company didn't disclose the name of the automaker. All the above lend credibility to QuantumScape's plans. If successful, QuantumScape's batteries could see immense demand from automakers worldwide.\nQuantumScape believes it is progressing as per its plan to start commercial production in 2024. That's a long time and the company's batteries are not yet developed. Investors should bear the risks in mind before deciding to invest in QuantumScape stock.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1046,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605620426,"gmtCreate":1639154224060,"gmtModify":1639154224060,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"great news","listText":"great news","text":"great news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/605620426","repostId":"1199826178","repostType":4,"repost":{"id":"1199826178","kind":"news","pubTimestamp":1639149380,"share":"https://www.laohu8.com/m/news/1199826178?lang=&edition=full","pubTime":"2021-12-10 23:16","market":"us","language":"en","title":"Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1199826178","media":"Bloomberg","summary":"Funds and researchers are scrutinized by Justice Department. Inquiry seeks information on trading in several dozen stocks. The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.The probe, run by the department’s fraud section with federal pro","content":"<ul>\n <li>Funds and researchers are scrutinized by Justice Department</li>\n <li>Inquiry seeks information on trading in several dozen stocks</li>\n</ul>\n<p>The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.</p>\n<p>The probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.</p>\n<p>Authorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.</p>\n<p>Underscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as&nbsp;Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc&nbsp;and&nbsp;GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based&nbsp;Anson Funds&nbsp;and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.</p>\n<p>The U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds&nbsp;threw in the towel&nbsp;as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.</p>\n<p>Meanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.</p>\n<p>Still, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.</p>\n<p>Government attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.</p>\n<p>Spokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.</p>\n<p>An attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.</p>\n<p>“Citron Capital&nbsp;and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”</p>\n<p><b>Funding Research</b></p>\n<p>Hedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said&nbsp;he partnered with a hedge fund to share profits when he released a report on&nbsp;General Electric Co.</p>\n<p>Some hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.</p>\n<p>One cautionary tale emerged in court after Dallas-based&nbsp;Sabrepoint Capital&nbsp;agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company&nbsp;Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.</p>\n<p>Mathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.</p>\n<p>Farmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.</p>\n<p>The Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase &amp; Co.&nbsp;paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.</p>\n<p>While prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.</p>\n<p>The inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of&nbsp;GameStop Corp.&nbsp;soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.</p>\n<p>Lawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.</p>\n<p>Concerns about how short sellers carry out attacks have arisen repeatedly over the years.</p>\n<p>The Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.</p>\n<p>But there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.</p>\n<p>Studies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.</p>\n<p>Mitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.</p>\n<p>Academics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.</p>\n<p>Early last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHedge Funds Ensnared in Expansive DOJ Probe Into Short Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯","BANC":"BANC OF CALIFORNIA","GE":"GE航空航天","MNKKQ":"Mallinckrodt plc.","GOTU":"高途","FPI":"Farmland Partners Inc","GME":"游戏驿站","LKNCY":"瑞幸咖啡",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199826178","content_text":"Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.\nThe probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.\nAuthorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.\nUnderscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc and GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based Anson Funds and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.\nThe U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds threw in the towel as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.\nMeanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.\nStill, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.\nGovernment attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.\nSpokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.\nAn attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.\n“Citron Capital and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”\nFunding Research\nHedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said he partnered with a hedge fund to share profits when he released a report on General Electric Co.\nSome hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.\nOne cautionary tale emerged in court after Dallas-based Sabrepoint Capital agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.\nMathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.\nFarmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.\nThe Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase & Co. paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.\nWhile prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.\nThe inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of GameStop Corp. soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.\nLawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.\nConcerns about how short sellers carry out attacks have arisen repeatedly over the years.\nThe Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.\nBut there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.\nStudies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.\nMitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.\nAcademics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.\nEarly last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1082,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607885507,"gmtCreate":1639525286798,"gmtModify":1639525286861,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"When does this end?","listText":"When does this end?","text":"When does this end?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607885507","repostId":"2191784951","repostType":4,"repost":{"id":"2191784951","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639522244,"share":"https://www.laohu8.com/m/news/2191784951?lang=&edition=full","pubTime":"2021-12-15 06:50","market":"us","language":"en","title":"Wall Street ends down, investors eye inflation and Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2191784951","media":"Reuters","summary":"* Fed policy decision awaited on Wednesday\n* November PPI logs highest rise since 2010\n* Tech leads ","content":"<p>* Fed policy decision awaited on Wednesday</p>\n<p>* November PPI logs highest rise since 2010</p>\n<p>* Tech leads declines, financials rally</p>\n<p>* Indexes: Dow -0.30%, S&amp;P 500 -0.75%, Nasdaq -1.14%</p>\n<p>Dec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.</p>\n<p>The fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&amp;P 500 index hit an all-time closing high late last week.</p>\n<p>Declines were led by megacap tech-related stocks, with <a href=\"https://laohu8.com/S/CRM\">Salesforce</a>.com, Microsoft Corp, <a href=\"https://laohu8.com/S/ADBE\">Adobe</a> and Alphabet Inc pulling down the S&amp;P 500 and Nasdaq.</p>\n<p>Apple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.</p>\n<p>The Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&amp;P 500 lost 0.75% to 4,634.09.</p>\n<p>The Nasdaq Composite dropped 1.14% to 15,237.64.</p>\n<p>Data from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.</p>\n<p>About two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.</p>\n<p>\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.</p>\n<p>Berkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&amp;P 500 from falling further.</p>\n<p>Many investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.</p>\n<p>\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6ea56cda700f032a3421aa26db08524\" tg-width=\"596\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Inflation</span></p>\n<p>Beyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"</p>\n<p>Pfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.</p>\n<p>Volume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down, investors eye inflation and Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down, investors eye inflation and Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-15 06:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* Fed policy decision awaited on Wednesday</p>\n<p>* November PPI logs highest rise since 2010</p>\n<p>* Tech leads declines, financials rally</p>\n<p>* Indexes: Dow -0.30%, S&amp;P 500 -0.75%, Nasdaq -1.14%</p>\n<p>Dec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.</p>\n<p>The fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&amp;P 500 index hit an all-time closing high late last week.</p>\n<p>Declines were led by megacap tech-related stocks, with <a href=\"https://laohu8.com/S/CRM\">Salesforce</a>.com, Microsoft Corp, <a href=\"https://laohu8.com/S/ADBE\">Adobe</a> and Alphabet Inc pulling down the S&amp;P 500 and Nasdaq.</p>\n<p>Apple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.</p>\n<p>The Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&amp;P 500 lost 0.75% to 4,634.09.</p>\n<p>The Nasdaq Composite dropped 1.14% to 15,237.64.</p>\n<p>Data from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.</p>\n<p>About two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.</p>\n<p>\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"</p>\n<p>Ten of the 11 major S&amp;P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.</p>\n<p>Berkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&amp;P 500 from falling further.</p>\n<p>Many investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.</p>\n<p>\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.</p>\n<p>A Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a6ea56cda700f032a3421aa26db08524\" tg-width=\"596\" tg-height=\"500\" width=\"100%\" height=\"auto\"><span>Inflation</span></p>\n<p>Beyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"</p>\n<p>Pfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.</p>\n<p>Volume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SSO":"两倍做多标普500ETF","BK4559":"巴菲特持仓",".DJI":"道琼斯","BK4550":"红杉资本持仓","SPXU":"三倍做空标普500ETF","BK4079":"房地产服务","SPY":"标普500ETF","OEF":"标普100指数ETF-iShares","BK4504":"桥水持仓",".IXIC":"NASDAQ Composite","SDS":"两倍做空标普500ETF",".SPX":"S&P 500 Index","AAPL":"苹果","BK4539":"次新股","COMP":"Compass, Inc.","OEX":"标普100","BK4534":"瑞士信贷持仓","SH":"标普500反向ETF","IVV":"标普500指数ETF","UPRO":"三倍做多标普500ETF"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191784951","content_text":"* Fed policy decision awaited on Wednesday\n* November PPI logs highest rise since 2010\n* Tech leads declines, financials rally\n* Indexes: Dow -0.30%, S&P 500 -0.75%, Nasdaq -1.14%\nDec 14 (Reuters) - Wall Street ended lower on Tuesday after data showed producer prices increased more than expected in November, solidifying expectations the Federal Reserve this week will announce a faster wind-down of asset purchases.\nThe fast-spreading Omicron coronavirus variant also dampened investor sentiment after the S&P 500 index hit an all-time closing high late last week.\nDeclines were led by megacap tech-related stocks, with Salesforce.com, Microsoft Corp, Adobe and Alphabet Inc pulling down the S&P 500 and Nasdaq.\nApple Inc ended down 0.8%, but off its session lows, after the iPhone maker said it would require customers and employees to wear masks at its U.S. retail stores as COVID-19 cases surge.\nThe Dow Jones Industrial Average fell 0.3% to end at 35,544.18 points, while the S&P 500 lost 0.75% to 4,634.09.\nThe Nasdaq Composite dropped 1.14% to 15,237.64.\nData from the Labor Department showed the producer price index (PPI) for final demand in the 12 months through November shot up 9.6%, clocking its largest gain since November 2010. That followed an 8.8% increase in October.\nAbout two-thirds of Nasdaq stocks traded below their 200-day moving average, according to Refinitiv data, suggesting many stocks within the index are struggling, even as the overall index remains only about 6% below its November record high close.\n\"COVID plus inflation is the Grinch that stole Christmas,\" said Jake Dollarhide, chief executive officer at Longbow Asset Management. \"I don’t underestimate the fact that there are some big Nasdaq names giving up some of their big gains. When the leaders sell off, it's not a good sign.\"\nTen of the 11 major S&P 500 sector indexes fell, with tech putting on the worst performance, down 1.6%. Financials gained 0.6% as investors bet on a hawkish tone from the Fed at the end of its two-day meeting on Wednesday.\nBerkshire Hathaway and Bank of America both gained more than 1% and helped keep the S&P 500 from falling further.\nMany investors expect the U.S. central bank to signal a faster wind-down of asset purchases, and thus, a quicker start to interest rate hikes in order to contain the rapid rise in prices.\n\"I would say this meeting is when we start to get some clarity on how they're (the Fed) going to address this idea of inflation that has remained elevated and most likely will remain an issue going into next year,\" said David Keller, chief market strategist at StockCharts.com.\nA Reuters poll of economists sees the central bank hiking interest rates from near zero to 0.25%-0.50% in the third quarter of next year, followed by another in the fourth quarter.\nInflation\nBeyond Meat Inc rallied 9.3% after Piper Sandler upgraded the plant-based meat maker's stock to \"neutral\" from \"underweight.\"\nPfizer gained 0.6% after saying its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and that lab data suggests the drug retains its effectiveness against the Omicron variant.\nDeclining issues outnumbered advancing ones on the NYSE by a 2.70-to-1 ratio; on Nasdaq, a 2.59-to-1 ratio favored decliners.\nThe S&P 500 posted 15 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 18 new highs and 408 new lows.\nVolume on U.S. exchanges was 10.8 billion shares, compared with the 11.5 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1252,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604362023,"gmtCreate":1639351900923,"gmtModify":1639351900994,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"missed the Nvidia train 😢","listText":"missed the Nvidia train 😢","text":"missed the Nvidia train 😢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/604362023","repostId":"2190992671","repostType":4,"repost":{"id":"2190992671","kind":"highlight","pubTimestamp":1639280162,"share":"https://www.laohu8.com/m/news/2190992671?lang=&edition=full","pubTime":"2021-12-12 11:36","market":"hk","language":"en","title":"3 Top Metaverse Stocks to Buy in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2190992671","media":"Motley Fool","summary":"Investors have opportunities to build ground-floor positions in the metaverse revolution.","content":"<p>The rise of the metaverse could usher in a new age of commerce and socialization in virtual worlds. This potentially revolutionary trend is just starting to unfold, and businesses and investors alike are scrambling to get in on the ground floor.</p>\n<p>As an emerging medium, it's fair to say the metaverse is a relatively high-risk investment category, but people who back the right companies and projects could go on to enjoy stellar returns over the long term. With that in mind, read on for a look at three top metaverse stocks that are worth adding to your portfolio before the month is out.</p>\n<p><img src=\"https://static.tigerbbs.com/d47eead465efdbbba1ee3bfe3eb56002\" tg-width=\"700\" tg-height=\"467\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h2>1. <a href=\"https://laohu8.com/S/FB\">Meta Platforms</a></h2>\n<p>If you had to pick just <a href=\"https://laohu8.com/S/AONE.U\">one</a> company that appears to be positioning itself to lead the charge on the metaverse, <b>Meta Platforms</b> (NASDAQ:FB) would have to be as strong a choice as any. The company's belief in virtual worlds as a major step forward and revolutionary opportunity is so strong that CEO Mark Zuckerberg and his company opted to change the business's name from Facebook to one that reflects its big new growth bet.</p>\n<p>Meta Platforms' incredible resources and massive active user base give the company strong foundations to launch its metaverse projects. Between Facebook, Instagram, and WhatsApp, the company operates some of the world's most popular social media and communications platforms. The company ended its last quarter with 3.6 billion monthly active users -- good for roughly 45% of the world's population.</p>\n<p>In addition to its massive reach and development resources, Meta Platforms has also been an early mover in the metaverse. Even before the term \"metaverse\" entered into the popular lexicon, the company was eyeing virtual reality (VR) as the next revolutionary computing platform. The tech giant's VR division is at the forefront of hardware (through its Oculus headsets) and software in the category, and the company's big acquisitions should help solidify its leadership position in interactive virtual content and services.</p>\n<h2>2. Unity Software</h2>\n<p>Creating immersive virtual worlds is a complex process, but <b>Unity Software</b> (NYSE:U) offers software that can make it much easier. The company provides a development engine for video games and interactive experiences, and it's poised to help usher in the age of the metaverse. With Unity's tools and services, even relatively small teams can craft engaging visuals and worlds that go on to be enjoyed by a wide audience.</p>\n<p>Unity has already emerged as a go-to development engine for the creation of AR (augmented reality) and VR experiences, with roughly 60% of applications in the combined categories using its tools. Roughly 71% of this year's top 1,000 mobile games were also built using the company's development resources.</p>\n<p>Unity managed to grow sales 43% year over year in its most recently reported quarter, particularly impressive because it was lapping a year of explosive growth in 2020. As demand for metaverse content and services increases, Unity looks uniquely well-positioned to help a wide variety of businesses find success in the emerging medium.</p>\n<h2>3. Nvidia</h2>\n<p>Whether through local devices or cloud-based computing platforms, powerful computing hardware is going to play a big role in the evolution of the metaverse. <b>Nvidia</b> (NASDAQ:NVDA) is the leading provider of graphics processing units (GPUs), and the semiconductor specialist will likely be a key components provider for the evolution of virtual worlds.</p>\n<p>In addition to its hardware business, Nvidia is also positioning itself to benefit from the metaverse trend with its Omniverse software platform. Omniverse is a development, productivity, and sharing service tailored for the creation of metaverse experiences, which could turn into a major performance driver for the company.</p>\n<p>Nvidia is already generating very strong margins and looks poised to retain its leadership position in the GPU space. The addition of a substantial software-as-a-service (SaaS) component to its business model could add a major new source of revenue and push its margins even higher.</p>\n<p>Because of long-term growth opportunities for the company's processors in the gaming, cloud computing, artificial intelligence, and machine vision fields, the graphics specialist already had a promising outlook, and the rise of the metaverse is presenting another potentially explosive growth opportunity.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Metaverse Stocks to Buy in December</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Metaverse Stocks to Buy in December\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-12 11:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/11/3-top-metaverse-stocks-to-buy-in-december/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The rise of the metaverse could usher in a new age of commerce and socialization in virtual worlds. This potentially revolutionary trend is just starting to unfold, and businesses and investors alike ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/11/3-top-metaverse-stocks-to-buy-in-december/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4507":"流媒体概念","BK4525":"远程办公概念","NVDA":"英伟达","BK4524":"宅经济概念","BK4508":"社交媒体","BK4543":"AI","BK4077":"互动媒体与服务","BK4527":"明星科技股","BK4550":"红杉资本持仓","BK4141":"半导体产品","BK4503":"景林资产持仓","BK4551":"寇图资本持仓","BK4549":"软银资本持仓","BK4548":"巴美列捷福持仓","BK4529":"IDC概念","VR":"GLOBAL X METAVERSE ETF","BK4023":"应用软件","BK4554":"元宇宙及AR概念","U":"Unity Software Inc.","BK4532":"文艺复兴科技持仓","BK4553":"喜马拉雅资本持仓","BK4567":"ESG概念","BK4534":"瑞士信贷持仓"},"source_url":"https://www.fool.com/investing/2021/12/11/3-top-metaverse-stocks-to-buy-in-december/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2190992671","content_text":"The rise of the metaverse could usher in a new age of commerce and socialization in virtual worlds. This potentially revolutionary trend is just starting to unfold, and businesses and investors alike are scrambling to get in on the ground floor.\nAs an emerging medium, it's fair to say the metaverse is a relatively high-risk investment category, but people who back the right companies and projects could go on to enjoy stellar returns over the long term. With that in mind, read on for a look at three top metaverse stocks that are worth adding to your portfolio before the month is out.\n\nImage source: Getty Images.\n1. Meta Platforms\nIf you had to pick just one company that appears to be positioning itself to lead the charge on the metaverse, Meta Platforms (NASDAQ:FB) would have to be as strong a choice as any. The company's belief in virtual worlds as a major step forward and revolutionary opportunity is so strong that CEO Mark Zuckerberg and his company opted to change the business's name from Facebook to one that reflects its big new growth bet.\nMeta Platforms' incredible resources and massive active user base give the company strong foundations to launch its metaverse projects. Between Facebook, Instagram, and WhatsApp, the company operates some of the world's most popular social media and communications platforms. The company ended its last quarter with 3.6 billion monthly active users -- good for roughly 45% of the world's population.\nIn addition to its massive reach and development resources, Meta Platforms has also been an early mover in the metaverse. Even before the term \"metaverse\" entered into the popular lexicon, the company was eyeing virtual reality (VR) as the next revolutionary computing platform. The tech giant's VR division is at the forefront of hardware (through its Oculus headsets) and software in the category, and the company's big acquisitions should help solidify its leadership position in interactive virtual content and services.\n2. Unity Software\nCreating immersive virtual worlds is a complex process, but Unity Software (NYSE:U) offers software that can make it much easier. The company provides a development engine for video games and interactive experiences, and it's poised to help usher in the age of the metaverse. With Unity's tools and services, even relatively small teams can craft engaging visuals and worlds that go on to be enjoyed by a wide audience.\nUnity has already emerged as a go-to development engine for the creation of AR (augmented reality) and VR experiences, with roughly 60% of applications in the combined categories using its tools. Roughly 71% of this year's top 1,000 mobile games were also built using the company's development resources.\nUnity managed to grow sales 43% year over year in its most recently reported quarter, particularly impressive because it was lapping a year of explosive growth in 2020. As demand for metaverse content and services increases, Unity looks uniquely well-positioned to help a wide variety of businesses find success in the emerging medium.\n3. Nvidia\nWhether through local devices or cloud-based computing platforms, powerful computing hardware is going to play a big role in the evolution of the metaverse. Nvidia (NASDAQ:NVDA) is the leading provider of graphics processing units (GPUs), and the semiconductor specialist will likely be a key components provider for the evolution of virtual worlds.\nIn addition to its hardware business, Nvidia is also positioning itself to benefit from the metaverse trend with its Omniverse software platform. Omniverse is a development, productivity, and sharing service tailored for the creation of metaverse experiences, which could turn into a major performance driver for the company.\nNvidia is already generating very strong margins and looks poised to retain its leadership position in the GPU space. The addition of a substantial software-as-a-service (SaaS) component to its business model could add a major new source of revenue and push its margins even higher.\nBecause of long-term growth opportunities for the company's processors in the gaming, cloud computing, artificial intelligence, and machine vision fields, the graphics specialist already had a promising outlook, and the rise of the metaverse is presenting another potentially explosive growth opportunity.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1380,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3583318222987864","authorId":"3583318222987864","name":"TheMilkyWay","avatar":"https://static.tigerbbs.com/190d59bcbcc876e15543cbd430d8c1f2","crmLevel":3,"crmLevelSwitch":0,"idStr":"3583318222987864","authorIdStr":"3583318222987864"},"content":"Have not missed yet, the semi stocks are pulling back now. Maybe will have chance to jump onboard soon? Anyway so much upside potential, good to hold longterm.","text":"Have not missed yet, the semi stocks are pulling back now. Maybe will have chance to jump onboard soon? Anyway so much upside potential, good to hold longterm.","html":"Have not missed yet, the semi stocks are pulling back now. Maybe will have chance to jump onboard soon? Anyway so much upside potential, good to hold longterm."}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605629851,"gmtCreate":1639154390585,"gmtModify":1639154390585,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Crwd good choice","listText":"Crwd good choice","text":"Crwd good choice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605629851","repostId":"2190296066","repostType":4,"isVote":1,"tweetType":1,"viewCount":1255,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":344228861,"gmtCreate":1618411197453,"gmtModify":1634293117285,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"BTWN for the win!","listText":"BTWN for the win!","text":"BTWN for the win!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/344228861","repostId":"1106153811","repostType":4,"repost":{"id":"1106153811","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1618409078,"share":"https://www.laohu8.com/m/news/1106153811?lang=&edition=full","pubTime":"2021-04-14 22:04","market":"us","language":"en","title":"Some SPACs Could Fail Outright, Research Is Paramount: Cathie Wood","url":"https://stock-news.laohu8.com/highlight/detail?id=1106153811","media":"Benzinga","summary":"An Ark Investwebinarwas held on April 13. Among the topics discussed by CEOCathie Woodand the team w","content":"<p>An Ark Investwebinarwas held on April 13. Among the topics discussed by CEOCathie Woodand the team were SPACs.</p>\n<p><b>Caution On SPACs:</b>Ark Invest and Cathie Wood have two points of view when it comes to SPACs: \"We share optimism and concern.\"</p>\n<p>Wood said the compensation structure of SPACs deprives individual investors and rewards the sponsors of SPACs.</p>\n<p>The large number of SPACs and early-stage companies going public is another cautionary item. The venture capital model of getting two out of 10 deals right is good for VC but not how equity markets operate, according to Wood.</p>\n<p>“We think there will be some accidents in the SPAC market,\" she said.</p>\n<p>Wood said&nbsp;some of the companies going public via SPAC could fail outright.</p>\n<p><b>Research Is Paramount:</b>Wood said there are too many good opportunities in the SPAC investment segment and there are some great companies going public via this option though.</p>\n<p>“We’ve known many of the companies that have been acquired by SPACs,” Wood said, adding that they watched the companies prior to them going public. Wood mentioned 3D printing and drones specifically when discussing some areas that have had good SPAC deals.</p>\n<p>“Research is paramount,\" she said.</p>\n<p>Ark Invest has invested in several SPACs over the last 12 months. Among the 3D printing and drone companies owned by the ETF company are<b>Jaws Spitfire Acquisition Corp</b>SPFR 0.17%,<b>One</b>AONE 0.09%,<b>Desktop Metal Inc</b>DM 1.16%,<b>Reinvent Technology Partners</b>RTP 0.3%,<b>Experience Investment Corp</b>EXPC 0.07%and<b>Atlas Crest Investment Corp</b>ACIC 0.07%.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some SPACs Could Fail Outright, Research Is Paramount: Cathie Wood</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome SPACs Could Fail Outright, Research Is Paramount: Cathie Wood\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-04-14 22:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>An Ark Investwebinarwas held on April 13. Among the topics discussed by CEOCathie Woodand the team were SPACs.</p>\n<p><b>Caution On SPACs:</b>Ark Invest and Cathie Wood have two points of view when it comes to SPACs: \"We share optimism and concern.\"</p>\n<p>Wood said the compensation structure of SPACs deprives individual investors and rewards the sponsors of SPACs.</p>\n<p>The large number of SPACs and early-stage companies going public is another cautionary item. The venture capital model of getting two out of 10 deals right is good for VC but not how equity markets operate, according to Wood.</p>\n<p>“We think there will be some accidents in the SPAC market,\" she said.</p>\n<p>Wood said&nbsp;some of the companies going public via SPAC could fail outright.</p>\n<p><b>Research Is Paramount:</b>Wood said there are too many good opportunities in the SPAC investment segment and there are some great companies going public via this option though.</p>\n<p>“We’ve known many of the companies that have been acquired by SPACs,” Wood said, adding that they watched the companies prior to them going public. Wood mentioned 3D printing and drones specifically when discussing some areas that have had good SPAC deals.</p>\n<p>“Research is paramount,\" she said.</p>\n<p>Ark Invest has invested in several SPACs over the last 12 months. Among the 3D printing and drone companies owned by the ETF company are<b>Jaws Spitfire Acquisition Corp</b>SPFR 0.17%,<b>One</b>AONE 0.09%,<b>Desktop Metal Inc</b>DM 1.16%,<b>Reinvent Technology Partners</b>RTP 0.3%,<b>Experience Investment Corp</b>EXPC 0.07%and<b>Atlas Crest Investment Corp</b>ACIC 0.07%.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1106153811","content_text":"An Ark Investwebinarwas held on April 13. Among the topics discussed by CEOCathie Woodand the team were SPACs.\nCaution On SPACs:Ark Invest and Cathie Wood have two points of view when it comes to SPACs: \"We share optimism and concern.\"\nWood said the compensation structure of SPACs deprives individual investors and rewards the sponsors of SPACs.\nThe large number of SPACs and early-stage companies going public is another cautionary item. The venture capital model of getting two out of 10 deals right is good for VC but not how equity markets operate, according to Wood.\n“We think there will be some accidents in the SPAC market,\" she said.\nWood said some of the companies going public via SPAC could fail outright.\nResearch Is Paramount:Wood said there are too many good opportunities in the SPAC investment segment and there are some great companies going public via this option though.\n“We’ve known many of the companies that have been acquired by SPACs,” Wood said, adding that they watched the companies prior to them going public. Wood mentioned 3D printing and drones specifically when discussing some areas that have had good SPAC deals.\n“Research is paramount,\" she said.\nArk Invest has invested in several SPACs over the last 12 months. Among the 3D printing and drone companies owned by the ETF company areJaws Spitfire Acquisition CorpSPFR 0.17%,OneAONE 0.09%,Desktop Metal IncDM 1.16%,Reinvent Technology PartnersRTP 0.3%,Experience Investment CorpEXPC 0.07%andAtlas Crest Investment CorpACIC 0.07%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":609296965,"gmtCreate":1638284483570,"gmtModify":1638284483570,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"What about Arcturus? $ARCT","listText":"What about Arcturus? $ARCT","text":"What about Arcturus? $ARCT","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609296965","repostId":"1190156196","repostType":2,"repost":{"id":"1190156196","kind":"news","pubTimestamp":1638242388,"share":"https://www.laohu8.com/m/news/1190156196?lang=&edition=full","pubTime":"2021-11-30 11:19","market":"us","language":"en","title":"5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1190156196","media":"InvestorPlace","summary":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race","content":"<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537aabc5fd6c7ca4f614ce1b37dc0a75\" tg-width=\"1024\" tg-height=\"576\" width=\"100%\" height=\"auto\"><span>Source: Shutterstock</span></p>\n<p>As Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?</p>\n<p>Investors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.</p>\n<p>While&nbsp;<b>Pfizer’s</b>(NYSE:<b><u>PFE</u></b>)&nbsp;success in&nbsp;producing&nbsp;a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.</p>\n<p>Many vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.</p>\n<ul>\n <li><b>Moderna</b>(NASDAQ:<b><u>MRNA</u></b>)</li>\n <li><b>Pfizer</b>(NYSE:<b><u>PFE</u></b>)</li>\n <li><b>BioNTech</b>&nbsp;(NASDAQ:<b><u>BNTX</u></b>)</li>\n <li><b>Johnson &amp; Johnson</b>(NYSE:<b><u>JNJ</u></b>)</li>\n <li><b>Novavax</b>(NASDAQ:<b><u>NVAX</u></b>)</li>\n</ul>\n<p><b>Moderna (MRNA)</b></p>\n<p>Moderna was one of the first companies to have its executive team discuss address the omicron variant.</p>\n<p>On Sunday, CMO Paul Burton spoke to<i>BBC’s</i>Andrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketo<i>CNBC’s</i>“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.</p>\n<p>Bancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.</p>\n<p>This talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.</p>\n<p>While&nbsp;the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p>\n<p>\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times&nbsp;in an interview.</p>\n<p>\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p>\n<p><b>Pfizer (PFE)</b></p>\n<p>No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one&nbsp;<i>InvestorPlace</i>&nbsp;contributorfor CEO of the year.</p>\n<p>The industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.</p>\n<p>Clinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.</p>\n<p>While Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.</p>\n<p>It is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.</p>\n<p><b>BioNTech (BNTX)</b></p>\n<p>Pfizer’s original vaccine partner isn’t missing a beat, either.</p>\n<p>The German biotech innovatortold<i>Business Insider</i>that it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.</p>\n<p>Like its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.</p>\n<p>Like other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,<i>InvestorPlace</i>&nbsp;analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.</p>\n<p><b>Johnson &amp; Johnson (JNJ)</b></p>\n<p>Like its competitors, Johnson &amp; Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”</p>\n<p>Mathai Mammen, global head of research and development at J&amp;J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.</p>\n<p>Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.</p>\n<p><b>Novavax (NVAX)</b></p>\n<p>A later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.</p>\n<p>However, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”</p>\n<p>While Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.</p>\n<p>As&nbsp;<i>InvestorPlace</i>&nbsp;Assistant News Writer&nbsp;Eddie Pan&nbsp;reported&nbsp;this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-30 11:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis ...</p>\n\n<a href=\"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","JNJ":"强生","PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://investorplace.com/2021/11/5-vaccine-stocks-to-watch-as-new-covid-19-variant-strikes-the-market/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1190156196","content_text":"Here are the stocks to watch as the omicron variant gives rise to a new vaccine race\nSource: Shutterstock\nAs Black Friday approached, most investors were speculating on what the supply chain crisis would mean for the year’s biggest shopping holiday. By the time shopping began, though, most minds were on another news story. A new Covid-19 variant had been detected in South Africa and it was quickly spreading to Europe. Labeled the omicron variant, this new Covid-19 strain poses a threat to the pandemic recovery story. Perhaps most importantly, we don’t yet know how big that threat is. Scientists haveindicatedthat it will take at least a few weeks for them to assess the effectiveness of vaccines against the new variant, which features multiple mutations. As investors ponder what this means for markets, focus has shifted to one specific question: What does this mean for vaccine stocks?\nInvestors have expressed concern at what the the emergence of a new variant may mean for markets. It bears noting, though, that such a scenario creates a new opportunity for vaccine stocks, specifically for a new company to pull into the lead.\nWhile Pfizer’s(NYSE:PFE) success in producing a vaccine approved for children has helped it maintain a lead over its competitors, other companies recognize the need for further innovation within the vaccine space. Scientists and researchers have yet to reach a conclusion as to how the new variant will react to current vaccines, but the companies producing them are already working around the clock.\nMany vaccine stocks were trending this morning as the omicron variant dominated news coverage. Let’s take a look at what the most prominent vaccine producers are saying and when we can expect to see progress.\n\nModerna(NASDAQ:MRNA)\nPfizer(NYSE:PFE)\nBioNTech (NASDAQ:BNTX)\nJohnson & Johnson(NYSE:JNJ)\nNovavax(NASDAQ:NVAX)\n\nModerna (MRNA)\nModerna was one of the first companies to have its executive team discuss address the omicron variant.\nOn Sunday, CMO Paul Burton spoke toBBC’sAndrew Marr and said Moderna was hoping to see clinical trials of an omicron-specific booster begin within60 to 90 days. CEO Stephane Bancel recentlyspoketoCNBC’s“Squawk Box” on the topic of an omicron- targeting vaccine. While he stated that it will likely take months for the company to develop, produce and ship a vaccine with the ability to target that specific variant, he noted that a booster shot containing a higher 100-microgram dose could be made available much sooner.\nBancel also floated the possibility of administering higher doses of the current vaccines to particularly high-risk patients, such as those in the elderly or immunocompromised categories.\nThis talk of an effective booster that could take on the new variant has sent MRNA stock shooting up today. As of this writing, vaccine stocks are having a good day and Moderna has risen by more than 10%. Today’s gains have put it up by more than 30% for the past five days.\nWhile the head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nPfizer (PFE)\nNo pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla wasrecommended by one InvestorPlace contributorfor CEO of the year.\nThe industry leader alsodiscussedthe new variant earlier today, stating that he believed that Pfizer’s Covid-19 pill would prove effective against it. He noted that the treatment method was designed with the thought process that most virus mutations were coming in spikes, exactly what we are seeing so far from the omicron variant. This gives him, he said, a “very high level of confidence” that the oral treatment, Paxlovid, will prove well-suited to help patients with the new Covid-19 strain.\nClinical trials have found that when Paxlovid is taken with HIV drug ritonavir, it reduces hospitalization and death by 89% if taken within three days after symptoms have begun.\nWhile Bourla is still not able to offer much on the effectiveness of the company’s two-dose vaccine against the new variant, he experts it to offer at least some protection. He also said that Pfizer is already at work on a new vaccine and that it produced a DNA template on Friday, speculating that it could be ready within 100 days.\nIt is worth noting that Pfizer has been able to create vaccines for previous variants in that timeframe but did not end up having to administer them, as the previously distributed vaccines remained effective.\nBioNTech (BNTX)\nPfizer’s original vaccine partner isn’t missing a beat, either.\nThe German biotech innovatortoldBusiness Insiderthat it is already at work on the development of an adapted vaccine to combat the omicron variant. According to the company’s spokespeople, the first steps of such a process “overlap with the research necessary” to evaluate the necessity of a new shot. This approach should enable its research team to move forward as quickly as possible.\nLike its competitors, BioNTech expects to acquire the data necessary to determine next steps in roughly two weeks, as medical researchers rush to examine new cases. In an attempt to keep the process as efficient as possible, the company is already testing its existing vaccine doses. Like Pfizer, it claims that it will be able to ship out this adapted vaccine within 100 days should it prove necessary.\nLike other vaccine stocks, BNTX is having a good day as speculation regarding the vaccine mounts. Shares are up almost 4% as of this writing. Not unlike its competitor Moderna, BioNTech is up almost 20% for the week after seeing a period of mostly flatlining. Earlier this Summer,InvestorPlace analyst Louis Navelliercalledit a better buy among vaccine stocks than Pfizer.\nJohnson & Johnson (JNJ)\nLike its competitors, Johnson & Johnson is already at work on ways to combat the new variant. Still waiting on further data, though, the company hasstatedit “will progress [its new vaccine] into clinical studies if needed.”\nMathai Mammen, global head of research and development at J&J subsidiary Janssen Pharmaceuticals, says that the company remains confident in the “robust humoral and cell-mediated responses” that its original vaccine has elicited in patients to date, giving the company confidence in its ability to adapt its current vaccine to handle the omicron variant.\nMammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary. It has beenreportedthat testing has already begun.\nNovavax (NVAX)\nA later player to the vaccine race, Novavax hasn’t had the same success in the U.S. as Pfizer or Moderna.\nHowever, the company recognizes it has a chance to make up the lost ground. In fact, it is already working to develop a vaccine to combat the omicron variant. Novavax hasstatedthat its vaccine will contain the mutated spikes that have experts worried about the variant, thereby enabling recipients to develop necessary immune responses. Its spokespeople have also stated that the testing and developing of the new vaccine will likely take “a few weeks.”\nWhile Novavax has not filed for approval for its initial Covid-19 in the U.S. yet, it received the green light from regulators in both Indonesia and the Philippines.\nAs InvestorPlace Assistant News Writer Eddie Pan reported this morning, NVAX is a name to watch among vaccine stocks as speculation mounts. While no one is likely to know too much for at least two weeks, companies aren’t wasting any time in building on their vaccine innovations in attempt to pull ahead in the vaccine race. Novavax may not have garnered U.S. authorization yet, but it has risen to prominence by way of its global vaccine distribution work, an edge that earned it ahigh rankingamong second-shot vaccine stocks to buy.","news_type":1},"isVote":1,"tweetType":1,"viewCount":639,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609239848,"gmtCreate":1638284771792,"gmtModify":1638284771792,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Get ARCT. Soon to be the vaccine that rulesthem all. 😬","listText":"Get ARCT. Soon to be the vaccine that rulesthem all. 😬","text":"Get ARCT. Soon to be the vaccine that rulesthem all. 😬","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609239848","repostId":"1167187587","repostType":4,"repost":{"id":"1167187587","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638282732,"share":"https://www.laohu8.com/m/news/1167187587?lang=&edition=full","pubTime":"2021-11-30 22:32","market":"us","language":"en","title":"Stocks open lower as investors assess omicron concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1167187587","media":"Tiger Newspress","summary":"Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks ","content":"<p>Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks associated with the new omicron Covid variant.</p>\n<p>The Dow Jones Industrial Average dropped about 290 points, or 0.8%. The S&amp;P 500 shed 0.64%. The technology-heavy Nasdaq Composite shed about 0.4%. The small-cap benchmark Russell 2000 dropped 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/078050fb74fa44676c309ee766ee815d\" tg-width=\"1080\" tg-height=\"472\" referrerpolicy=\"no-referrer\"></p>\n<p>Tuesday's reversal came after&nbsp;Moderna&nbsp;CEO Stephane Bancel told the Financial Times that he&nbsp;expects existing vaccines to be less effective&nbsp;against the new variant. The CEO told the paper there could be a \"material drop\" in the current vaccines' effectiveness against this variant. Bancel told CNBC on Monday that it could take&nbsp;months to develop and ship an omicron-specific vaccine. Moderna was down nearly 4%.</p>\n<p>Separately,Regeneron&nbsp;said its antibody treatment may have reduced effectiveness against omicron. Regeneron shares lost about 1%.</p>\n<p>Travel shares, which led Friday's drop and then gained on Monday, were taking hits once again Tuesday.Expedia Group&nbsp;fell 2%,Norwegian Cruise Line Holdings&nbsp;and&nbsp;American Airlines&nbsp;&nbsp;shares&nbsp;tumbled about&nbsp;2%.</p>\n<p>Bucking the broader market's trend, stay-at-home stock Netflix rose 1.4% and Tesla gained 1.5%.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks open lower as investors assess omicron concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks open lower as investors assess omicron concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-30 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks associated with the new omicron Covid variant.</p>\n<p>The Dow Jones Industrial Average dropped about 290 points, or 0.8%. The S&amp;P 500 shed 0.64%. The technology-heavy Nasdaq Composite shed about 0.4%. The small-cap benchmark Russell 2000 dropped 0.7%.</p>\n<p><img src=\"https://static.tigerbbs.com/078050fb74fa44676c309ee766ee815d\" tg-width=\"1080\" tg-height=\"472\" referrerpolicy=\"no-referrer\"></p>\n<p>Tuesday's reversal came after&nbsp;Moderna&nbsp;CEO Stephane Bancel told the Financial Times that he&nbsp;expects existing vaccines to be less effective&nbsp;against the new variant. The CEO told the paper there could be a \"material drop\" in the current vaccines' effectiveness against this variant. Bancel told CNBC on Monday that it could take&nbsp;months to develop and ship an omicron-specific vaccine. Moderna was down nearly 4%.</p>\n<p>Separately,Regeneron&nbsp;said its antibody treatment may have reduced effectiveness against omicron. Regeneron shares lost about 1%.</p>\n<p>Travel shares, which led Friday's drop and then gained on Monday, were taking hits once again Tuesday.Expedia Group&nbsp;fell 2%,Norwegian Cruise Line Holdings&nbsp;and&nbsp;American Airlines&nbsp;&nbsp;shares&nbsp;tumbled about&nbsp;2%.</p>\n<p>Bucking the broader market's trend, stay-at-home stock Netflix rose 1.4% and Tesla gained 1.5%.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1167187587","content_text":"Stocks tumbled on Tuesday, reversing Monday's rebound on Wall Street, as investors reassessed risks associated with the new omicron Covid variant.\nThe Dow Jones Industrial Average dropped about 290 points, or 0.8%. The S&P 500 shed 0.64%. The technology-heavy Nasdaq Composite shed about 0.4%. The small-cap benchmark Russell 2000 dropped 0.7%.\n\nTuesday's reversal came after Moderna CEO Stephane Bancel told the Financial Times that he expects existing vaccines to be less effective against the new variant. The CEO told the paper there could be a \"material drop\" in the current vaccines' effectiveness against this variant. Bancel told CNBC on Monday that it could take months to develop and ship an omicron-specific vaccine. Moderna was down nearly 4%.\nSeparately,Regeneron said its antibody treatment may have reduced effectiveness against omicron. Regeneron shares lost about 1%.\nTravel shares, which led Friday's drop and then gained on Monday, were taking hits once again Tuesday.Expedia Group fell 2%,Norwegian Cruise Line Holdings and American Airlines  shares tumbled about 2%.\nBucking the broader market's trend, stay-at-home stock Netflix rose 1.4% and Tesla gained 1.5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":877900584,"gmtCreate":1637852589386,"gmtModify":1637852589386,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"just keep buying!","listText":"just keep buying!","text":"just keep buying!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/877900584","repostId":"2186916023","repostType":2,"repost":{"id":"2186916023","kind":"highlight","pubTimestamp":1637848500,"share":"https://www.laohu8.com/m/news/2186916023?lang=&edition=full","pubTime":"2021-11-25 21:55","market":"us","language":"en","title":"Will Palantir Be a Trillion-Dollar Stock by 2040?","url":"https://stock-news.laohu8.com/highlight/detail?id=2186916023","media":"Motley Fool","summary":"The data-mining firm has a slim chance of eventually joining the 12-zero club.","content":"<p><b>Palantir Technologies</b> (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed more government and enterprise contracts.</p>\n<p>The bears pointed out that Palantir was too heavily dependent on government clients, its enterprise business faced too many competitors, it was deeply unprofitable, and its stock was too expensive.</p>\n<p>Palantir's stock price has experienced some wild swings over the past year, but it has still more than doubled since its first trade at $10 per share.</p>\n<p>Today, Palantir is valued at $41.3 billion, or 27 times this year's sales. The bears will argue that the high price-to-sales (P/S) ratio will limit its upside, especially as rising interest rates and inflation make many high-growth tech stocks less attractive.</p>\n<p>But let's look beyond the near-term noise and see if Palantir can still generate big multibagger gains, or even become a trillion-dollar stock, over the next two decades.</p>\n<h2>How fast is Palantir growing?</h2>\n<p>Palantir expects to grow its revenue by at least 30% annually between fiscal 2021 and 2025. That forecast implies its revenue will rise from its target of $1.5 billion this year to at least $4.3 billion in 2025.</p>\n<p>The company expects that growth to be driven by its new and expanded contracts with government agencies, as well as the growth of its Foundry platform for large commercial customers. The accelerating growth of its commercial business over the past year, which notably outpaced the growth of its government business last quarter, supports that thesis.</p>\n<h2>Palantir's path toward a trillion-dollar market cap</h2>\n<p>Palantir hasn't provided any longer-term targets beyond 2025. But based on the growth trajectory of other big data companies like <b><a href=\"https://laohu8.com/S/CRM\">Salesforce</a> </b>(NYSE:CRM), its annual revenue increase could potentially decelerate and stabilize at about 20% over the following 10 years.</p>\n<p>If it hits its target for 2025, then continues to grow its revenue at an average rate of 20% over the following 10 years, it could generate nearly $27 billion in revenue in 2035.</p>\n<p>If Palantir's revenue growth then slows down to 15% per year, which would be more comparable to <b>Microsoft</b>'s (NASDAQ:MSFT) current rate, it could generate over $53 billion in revenue in 2040.</p>\n<p>Assuming the company is still valued at over 20 times sales, its market cap could surpass $1 trillion. But most tech giants that grow their revenue 15% to 25% annually aren't valued at more than 20 times sales.</p>\n<p>Microsoft, which is expected to generate 17% sales growth this year, trades at 13 times that estimate. Salesforce, which is expected to generate 24% sales growth this year, trades at just 11 times this year's sales.</p>\n<p>Therefore, Palantir's market cap could potentially hit $1 trillion by 2040, but it seems highly unlikely. Instead, it will likely be closer to $500 billion (which would still be a 12-bagger gain from its current valuation) if its stock is trading at a more reasonable P/S ratio of 10.</p>\n<h2>Look beyond the market caps</h2>\n<p>Instead of focusing on Palantir's path toward joining the 12-zero club, investors should focus on its ability to generate sustainable growth.</p>\n<p>The company has gained a firm foothold with the U.S. government, but it still faces competition from internally developed systems. Immigration and Customs Enforcement (ICE), for example, has been developing its own platform to replace Palantir's Falcon. If other agencies follow ICE's lead, the company's dream of becoming the \"default operating system for data across the U.S. government\" could abruptly end.</p>\n<p>Palantir is making solid progress in the commercial market, but its Foundry platform still faces plenty of indirect competitors like <b>C3.ai</b>, <b>Salesforce</b>'s Tableau, and Glue from <b>Amazon</b> Web Services.</p>\n<p>The company likely believes its reputation as a battle-hardened platform for the U.S. military and government agencies will attract more enterprise customers. But there's no guarantee that this appeal will last for decades or fend off newer, hungrier, and more disruptive players in the data-mining market.</p>\n<h2>Is Palantir's stock still worth buying?</h2>\n<p>I still believe Palantir's stock is a promising long-term investment on the secular growth of the data-mining and analytics market. However, there's a lot of growth already baked into the stock, and its high valuations could limit its near-term and long-term potential. Palantir probably won't hit a trillion-dollar valuation within the next two decades, but it could still outperform the market and generate impressive multibagger gains.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Palantir Be a Trillion-Dollar Stock by 2040?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Palantir Be a Trillion-Dollar Stock by 2040?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-25 21:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Palantir Technologies (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://www.fool.com/investing/2021/11/25/will-palantir-be-a-trillion-dollar-stock-by-2040/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186916023","content_text":"Palantir Technologies (NYSE:PLTR) has been a volatile and polarizing investment since its direct listing last September. The bulls claimed its data-mining platforms would continue to grow as it signed more government and enterprise contracts.\nThe bears pointed out that Palantir was too heavily dependent on government clients, its enterprise business faced too many competitors, it was deeply unprofitable, and its stock was too expensive.\nPalantir's stock price has experienced some wild swings over the past year, but it has still more than doubled since its first trade at $10 per share.\nToday, Palantir is valued at $41.3 billion, or 27 times this year's sales. The bears will argue that the high price-to-sales (P/S) ratio will limit its upside, especially as rising interest rates and inflation make many high-growth tech stocks less attractive.\nBut let's look beyond the near-term noise and see if Palantir can still generate big multibagger gains, or even become a trillion-dollar stock, over the next two decades.\nHow fast is Palantir growing?\nPalantir expects to grow its revenue by at least 30% annually between fiscal 2021 and 2025. That forecast implies its revenue will rise from its target of $1.5 billion this year to at least $4.3 billion in 2025.\nThe company expects that growth to be driven by its new and expanded contracts with government agencies, as well as the growth of its Foundry platform for large commercial customers. The accelerating growth of its commercial business over the past year, which notably outpaced the growth of its government business last quarter, supports that thesis.\nPalantir's path toward a trillion-dollar market cap\nPalantir hasn't provided any longer-term targets beyond 2025. But based on the growth trajectory of other big data companies like Salesforce (NYSE:CRM), its annual revenue increase could potentially decelerate and stabilize at about 20% over the following 10 years.\nIf it hits its target for 2025, then continues to grow its revenue at an average rate of 20% over the following 10 years, it could generate nearly $27 billion in revenue in 2035.\nIf Palantir's revenue growth then slows down to 15% per year, which would be more comparable to Microsoft's (NASDAQ:MSFT) current rate, it could generate over $53 billion in revenue in 2040.\nAssuming the company is still valued at over 20 times sales, its market cap could surpass $1 trillion. But most tech giants that grow their revenue 15% to 25% annually aren't valued at more than 20 times sales.\nMicrosoft, which is expected to generate 17% sales growth this year, trades at 13 times that estimate. Salesforce, which is expected to generate 24% sales growth this year, trades at just 11 times this year's sales.\nTherefore, Palantir's market cap could potentially hit $1 trillion by 2040, but it seems highly unlikely. Instead, it will likely be closer to $500 billion (which would still be a 12-bagger gain from its current valuation) if its stock is trading at a more reasonable P/S ratio of 10.\nLook beyond the market caps\nInstead of focusing on Palantir's path toward joining the 12-zero club, investors should focus on its ability to generate sustainable growth.\nThe company has gained a firm foothold with the U.S. government, but it still faces competition from internally developed systems. Immigration and Customs Enforcement (ICE), for example, has been developing its own platform to replace Palantir's Falcon. If other agencies follow ICE's lead, the company's dream of becoming the \"default operating system for data across the U.S. government\" could abruptly end.\nPalantir is making solid progress in the commercial market, but its Foundry platform still faces plenty of indirect competitors like C3.ai, Salesforce's Tableau, and Glue from Amazon Web Services.\nThe company likely believes its reputation as a battle-hardened platform for the U.S. military and government agencies will attract more enterprise customers. But there's no guarantee that this appeal will last for decades or fend off newer, hungrier, and more disruptive players in the data-mining market.\nIs Palantir's stock still worth buying?\nI still believe Palantir's stock is a promising long-term investment on the secular growth of the data-mining and analytics market. However, there's a lot of growth already baked into the stock, and its high valuations could limit its near-term and long-term potential. Palantir probably won't hit a trillion-dollar valuation within the next two decades, but it could still outperform the market and generate impressive multibagger gains.","news_type":1},"isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600844252,"gmtCreate":1638142736784,"gmtModify":1638142736784,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"How will it match up to rivals?","listText":"How will it match up to rivals?","text":"How will it match up to rivals?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600844252","repostId":"1103197941","repostType":4,"repost":{"id":"1103197941","kind":"news","pubTimestamp":1638141915,"share":"https://www.laohu8.com/m/news/1103197941?lang=&edition=full","pubTime":"2021-11-29 07:25","market":"us","language":"en","title":"Fisker unveils ‘world’s most sustainable vehicle’ as electric vehicle competition heats up","url":"https://stock-news.laohu8.com/highlight/detail?id=1103197941","media":"Yahoo","summary":"It seems among the investor community, all everyone talks about are the EV (electric vehicle) stocks","content":"<p>It seems among the investor community, all everyone talks about are the EV (electric vehicle) stocks - and only the big ones at that - Tesla (TSLA), Rivian (RIVN), and Lucid (LCID).</p>\n<p>One EV company that’s been flying under the radar, that is until it had big news at this year’s Los Angeles Auto show is Fisker Inc (FSR).</p>\n<p>Fisker, founded and run by legendary automotive designer Henrik Fisker, unveiled the production version of its Ocean EV SUV.</p>\n<p>Overall it's a competitive package, penned by Henrik himself, and in top trim form the Ocean is targeting over 350 miles of range from an all-wheel drive, dual motor setup pumping out 540 horsepower.</p>\n<p>While those are noteworthy figures, there are other EVs that can match these figures in that price range (around $65,000 for the higher end Ocean). The real twist here is the base Ocean, called the Ocean Sport, that will use a smaller range battery (targeting around 250 miles of range), and a single-motor front wheel drive, that will start — before any state and local incentives —at $37,499.</p>\n<p>At that price level, no one so far, even Tesla, can match that price in the premium EV landscape. Yahoo Finance spoke to Henrik Fisker at the LA auto show about how the company plans to make this pricing work.</p>\n<p>“We have a whole asset-light business model — it's a little bit like Apple (AAPL), Foxconn, if you want — in terms of we concentrate on the product, the marketing, the design, the development, and then we outsource manufacturing,” Fisker said from the company’s imposing stand on the convention floor. “We don't have to put thousands of dollars [in] each car because we have to keep the lights on in the factory, and pay real estate taxes and whatever it all is.”</p>\n<p>Fisker is using large contract manufacturer Magna (MGA) to build its Ocean SUV. Magna makes cars and large components for clients like BMW (BMWYY), GM (GM), and even Ferrari (RACE).</p>\n<p>In addition, one area that puts upward pressure on the price tags of EVs are batteries. Fisker is using CATL, the world’s largest battery manufacturer, to make a custom package for the Ocean, using cheaper LFP (lithium iron phosphate) battery cells for the Ocean Sport model, and more energy dense nickel manganese cobalt cells for the extended range Ocean trim levels.</p>\n<p>On top of all that, Fisker wants this car to be the most sustainable car on the planet — hence the name \"Ocean.\"</p>\n<p>“So the idea with this vehicle is to make it the world's most sustainable vehicle, so we've got a solar roof that can give you up to 1,500 miles for a year, we've got a fully vegan interior with recycled materials,” he says. Even all the carpets are made from recycled plastic bottles and fishing nets from the ocean, and the carbon fiber elements on the car and the wheels are, you guessed it, recycled.</p>\n<p>With 20,000 reservations in the order book right now, the company is seeing good interest in a car that won’t see the streets until the third quarter of 2022. But this is according to plan.</p>\n<p>Fisker understands that production, versus prototyping, is hard. Tesla’s Elon Musk says this almoston a weekly basis. It’s in an extremely complicated process that requires proper systems, technical partners, and of course, capital, to get right.</p>\n<p>The challenge for EV startups, Fisker says, is how to ramp up and produce several hundred thousand vehicles a year — and not take 10 years to do it. This is where Fisker’s partner Magna comes into a play, with its capability to produce thousands of cars of year, coupled with new capital raises the Fisker has made this year ($1 billion through its SPAC IPO and $600 million in a debt offering), to invest in R&amp;D and acquire know-how and parts from technical partners. It’s the only way startups can compete with the GMs and Fords (F) of the world.</p>\n<p>“A car is made of about 1,500 parts or even more, depending on how many screws you count, and all these parts have to come in just in time. They have to be put together exactly at the right time in the right sequence,” Fisker says. “I think most EV startups underestimate that. it has taken the traditional car industry many, many decades to perfect this, and that's what they're really good at.”</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fisker unveils ‘world’s most sustainable vehicle’ as electric vehicle competition heats up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFisker unveils ‘world’s most sustainable vehicle’ as electric vehicle competition heats up\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 07:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/fisker-unveils-worlds-most-sustainable-vehicle-as-electric-vehicle-competition-heats-up-141734654.html><strong>Yahoo</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It seems among the investor community, all everyone talks about are the EV (electric vehicle) stocks - and only the big ones at that - Tesla (TSLA), Rivian (RIVN), and Lucid (LCID).\nOne EV company ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fisker-unveils-worlds-most-sustainable-vehicle-as-electric-vehicle-competition-heats-up-141734654.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc","FSR":"菲斯克"},"source_url":"https://finance.yahoo.com/news/fisker-unveils-worlds-most-sustainable-vehicle-as-electric-vehicle-competition-heats-up-141734654.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103197941","content_text":"It seems among the investor community, all everyone talks about are the EV (electric vehicle) stocks - and only the big ones at that - Tesla (TSLA), Rivian (RIVN), and Lucid (LCID).\nOne EV company that’s been flying under the radar, that is until it had big news at this year’s Los Angeles Auto show is Fisker Inc (FSR).\nFisker, founded and run by legendary automotive designer Henrik Fisker, unveiled the production version of its Ocean EV SUV.\nOverall it's a competitive package, penned by Henrik himself, and in top trim form the Ocean is targeting over 350 miles of range from an all-wheel drive, dual motor setup pumping out 540 horsepower.\nWhile those are noteworthy figures, there are other EVs that can match these figures in that price range (around $65,000 for the higher end Ocean). The real twist here is the base Ocean, called the Ocean Sport, that will use a smaller range battery (targeting around 250 miles of range), and a single-motor front wheel drive, that will start — before any state and local incentives —at $37,499.\nAt that price level, no one so far, even Tesla, can match that price in the premium EV landscape. Yahoo Finance spoke to Henrik Fisker at the LA auto show about how the company plans to make this pricing work.\n“We have a whole asset-light business model — it's a little bit like Apple (AAPL), Foxconn, if you want — in terms of we concentrate on the product, the marketing, the design, the development, and then we outsource manufacturing,” Fisker said from the company’s imposing stand on the convention floor. “We don't have to put thousands of dollars [in] each car because we have to keep the lights on in the factory, and pay real estate taxes and whatever it all is.”\nFisker is using large contract manufacturer Magna (MGA) to build its Ocean SUV. Magna makes cars and large components for clients like BMW (BMWYY), GM (GM), and even Ferrari (RACE).\nIn addition, one area that puts upward pressure on the price tags of EVs are batteries. Fisker is using CATL, the world’s largest battery manufacturer, to make a custom package for the Ocean, using cheaper LFP (lithium iron phosphate) battery cells for the Ocean Sport model, and more energy dense nickel manganese cobalt cells for the extended range Ocean trim levels.\nOn top of all that, Fisker wants this car to be the most sustainable car on the planet — hence the name \"Ocean.\"\n“So the idea with this vehicle is to make it the world's most sustainable vehicle, so we've got a solar roof that can give you up to 1,500 miles for a year, we've got a fully vegan interior with recycled materials,” he says. Even all the carpets are made from recycled plastic bottles and fishing nets from the ocean, and the carbon fiber elements on the car and the wheels are, you guessed it, recycled.\nWith 20,000 reservations in the order book right now, the company is seeing good interest in a car that won’t see the streets until the third quarter of 2022. But this is according to plan.\nFisker understands that production, versus prototyping, is hard. Tesla’s Elon Musk says this almoston a weekly basis. It’s in an extremely complicated process that requires proper systems, technical partners, and of course, capital, to get right.\nThe challenge for EV startups, Fisker says, is how to ramp up and produce several hundred thousand vehicles a year — and not take 10 years to do it. This is where Fisker’s partner Magna comes into a play, with its capability to produce thousands of cars of year, coupled with new capital raises the Fisker has made this year ($1 billion through its SPAC IPO and $600 million in a debt offering), to invest in R&D and acquire know-how and parts from technical partners. It’s the only way startups can compete with the GMs and Fords (F) of the world.\n“A car is made of about 1,500 parts or even more, depending on how many screws you count, and all these parts have to come in just in time. They have to be put together exactly at the right time in the right sequence,” Fisker says. “I think most EV startups underestimate that. it has taken the traditional car industry many, many decades to perfect this, and that's what they're really good at.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":344225693,"gmtCreate":1618411319812,"gmtModify":1634293115193,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"PLTR ALL THE WAY!","listText":"PLTR ALL THE WAY!","text":"PLTR ALL THE WAY!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/344225693","repostId":"1193747033","repostType":4,"repost":{"id":"1193747033","kind":"news","pubTimestamp":1618404624,"share":"https://www.laohu8.com/m/news/1193747033?lang=&edition=full","pubTime":"2021-04-14 20:50","market":"us","language":"en","title":"The Bear Thesis Against Palantir Is Rooted in Illogical Conclusions","url":"https://stock-news.laohu8.com/highlight/detail?id=1193747033","media":"InvestorPlace","summary":"Follow the PLTR stock bull thesis and get in cheap.There’s a lot of negative sentiment surroundingPa","content":"<blockquote>Follow the PLTR stock bull thesis and get in cheap.</blockquote><p>There’s a lot of negative sentiment surrounding<b>Palantir</b>(NYSE:<b><u>PLTR</u></b>) stock. A good number of headlines will imply that the company hasn’t done well, or is suddenly at risk of implosion.</p><p>Yet, when you dig into the numbers and strategy, Palantir looks like a strong company underpinned by growth. The argument against Palantir usually centers around its controversial nature and the concentration of its business. Palantir’s controversial nature is largely subjective of course.</p><p>What I see when I dig into Palantir is a company that is improving and somewhat misunderstood. That’s why the bullish case for buying in at today’s low prices makes sense.</p><p><b>Longer Term</b></p><p>It’s easy to look at a given company’s stock and judge it by a slide in price or short-term negative news. Yet, when establishing a long-term, buy-and-hold position, it makes sense to consider a company’s performance on a year over year basis.</p><p>And that’s a good place to start to understand why PLTR stock is now an opportune purchase. The company only recently had its IPO in late September, so let’s look at some recent years’ broad metrics for Palantir.</p><p>Revenues, profits and margins are all improving at Palantir over the past few years. Investors shouldn’t get overly concerned that Palantir isn’t the largest defense contractor, or that Palantir has a business concentrated in that specific sector.</p><p>So, back to those revenue, profit, and margin metrics. Palantir’s 2020 revenues hit $1.1 billion, up 47% from 2019 when it recorded $742.6 million in revenues. The company’s gross profit in 2020 was $740.1 million, up from $500.2 million in 2019. That means the gross margin grew from 67% to 68% between 2019 and 2020.</p><p>Honestly, this broad growth is more indicative of a company that makes sense investment-wise. I’d argue that much of the negative sentiment against Palantir is from pundits who simply can’t or won’t see the forest for the trees.</p><p>So, let’s look at the trees clouding their vision.</p><p><b>Naysayers</b></p><p>Anargument I read from priorto Palantir’s IPO stated:</p><blockquote>For investors, the most concerning might be its high customer concentration. Palantir said its top 20 customers accounted for 67% of its 2019 revenue, while its top three customers made up 28%. In fact, a single commercial customer accounted for 12% of its 2019 revenue. Losing any one of those major customers could have a big financial impact on Palantir’s business.</blockquote><p>The argument relies on the idea that Palantir is incapable of maintaining the business relationship that it has forged in the private and public sectors.</p><p>But that doesn’t hold up based on Palantir’syear-end 2020 report.</p><p>Government customer revenue increased by 77% between 2019 and 2020 at Palantir. $234.3 million of that $264.7 million increase was attributable to existing customers. Therefore, 88% of the government revenue increase came from existing contracts. This is a company that is providing services that its clients respect and will pay more for over time, not one in danger of losing customers.</p><p>On the commercial side Palantir saw its revenues grow 22% in the same time frame. $59.7 million (69.9%) of the $85.4 million in revenue growth was from existing clients. Again, satisfied customers is the narrative I see here.</p><p>If Palantir is doing something wrong by expanding their business within the contracts they currently have, then what should they do? Would markets be more impressed if the company were to land clients only not to see their respective businesses grow on an account-by-account basis?</p><p>Show me that Palantir’s business isn’t growing based on revenues, profits or some other meaningful basis and I’d be inclined to be bearish long term. That isn’t the case.</p><p><b>Verdict</b></p><p>Bears are essentially arguing that Palantir keeps ingratiating themselves to those that they provide services for. However, Palantir simply continues to grow those businesses, and that’s somehow a bad thing?</p><p>Seems an odd argument to me.I think PLTR stock prices now are an excellent spot from which to establish a position.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Bear Thesis Against Palantir Is Rooted in Illogical Conclusions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Bear Thesis Against Palantir Is Rooted in Illogical Conclusions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-14 20:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/04/the-bear-thesis-against-pltr-stock-is-rooted-in-illogical-conclusions/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Follow the PLTR stock bull thesis and get in cheap.There’s a lot of negative sentiment surroundingPalantir(NYSE:PLTR) stock. A good number of headlines will imply that the company hasn’t done well, or...</p>\n\n<a href=\"https://investorplace.com/2021/04/the-bear-thesis-against-pltr-stock-is-rooted-in-illogical-conclusions/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PLTR":"Palantir Technologies Inc."},"source_url":"https://investorplace.com/2021/04/the-bear-thesis-against-pltr-stock-is-rooted-in-illogical-conclusions/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1193747033","content_text":"Follow the PLTR stock bull thesis and get in cheap.There’s a lot of negative sentiment surroundingPalantir(NYSE:PLTR) stock. A good number of headlines will imply that the company hasn’t done well, or is suddenly at risk of implosion.Yet, when you dig into the numbers and strategy, Palantir looks like a strong company underpinned by growth. The argument against Palantir usually centers around its controversial nature and the concentration of its business. Palantir’s controversial nature is largely subjective of course.What I see when I dig into Palantir is a company that is improving and somewhat misunderstood. That’s why the bullish case for buying in at today’s low prices makes sense.Longer TermIt’s easy to look at a given company’s stock and judge it by a slide in price or short-term negative news. Yet, when establishing a long-term, buy-and-hold position, it makes sense to consider a company’s performance on a year over year basis.And that’s a good place to start to understand why PLTR stock is now an opportune purchase. The company only recently had its IPO in late September, so let’s look at some recent years’ broad metrics for Palantir.Revenues, profits and margins are all improving at Palantir over the past few years. Investors shouldn’t get overly concerned that Palantir isn’t the largest defense contractor, or that Palantir has a business concentrated in that specific sector.So, back to those revenue, profit, and margin metrics. Palantir’s 2020 revenues hit $1.1 billion, up 47% from 2019 when it recorded $742.6 million in revenues. The company’s gross profit in 2020 was $740.1 million, up from $500.2 million in 2019. That means the gross margin grew from 67% to 68% between 2019 and 2020.Honestly, this broad growth is more indicative of a company that makes sense investment-wise. I’d argue that much of the negative sentiment against Palantir is from pundits who simply can’t or won’t see the forest for the trees.So, let’s look at the trees clouding their vision.NaysayersAnargument I read from priorto Palantir’s IPO stated:For investors, the most concerning might be its high customer concentration. Palantir said its top 20 customers accounted for 67% of its 2019 revenue, while its top three customers made up 28%. In fact, a single commercial customer accounted for 12% of its 2019 revenue. Losing any one of those major customers could have a big financial impact on Palantir’s business.The argument relies on the idea that Palantir is incapable of maintaining the business relationship that it has forged in the private and public sectors.But that doesn’t hold up based on Palantir’syear-end 2020 report.Government customer revenue increased by 77% between 2019 and 2020 at Palantir. $234.3 million of that $264.7 million increase was attributable to existing customers. Therefore, 88% of the government revenue increase came from existing contracts. This is a company that is providing services that its clients respect and will pay more for over time, not one in danger of losing customers.On the commercial side Palantir saw its revenues grow 22% in the same time frame. $59.7 million (69.9%) of the $85.4 million in revenue growth was from existing clients. Again, satisfied customers is the narrative I see here.If Palantir is doing something wrong by expanding their business within the contracts they currently have, then what should they do? Would markets be more impressed if the company were to land clients only not to see their respective businesses grow on an account-by-account basis?Show me that Palantir’s business isn’t growing based on revenues, profits or some other meaningful basis and I’d be inclined to be bearish long term. That isn’t the case.VerdictBears are essentially arguing that Palantir keeps ingratiating themselves to those that they provide services for. However, Palantir simply continues to grow those businesses, and that’s somehow a bad thing?Seems an odd argument to me.I think PLTR stock prices now are an excellent spot from which to establish a position.","news_type":1},"isVote":1,"tweetType":1,"viewCount":140,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":607885969,"gmtCreate":1639525247866,"gmtModify":1639525247866,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Save the world!","listText":"Save the world!","text":"Save the world!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607885969","repostId":"2191937155","repostType":4,"repost":{"id":"2191937155","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1639521474,"share":"https://www.laohu8.com/m/news/2191937155?lang=&edition=full","pubTime":"2021-12-15 06:37","market":"us","language":"en","title":"Pfizer says COVID-19 pill near 90% protective against hospitalization, death","url":"https://stock-news.laohu8.com/highlight/detail?id=2191937155","media":"Reuters","summary":"NEW YORK, Dec 14 (Reuters) - Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% ","content":"<p>NEW YORK, Dec 14 (Reuters) - Pfizer Inc&nbsp;on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.</p>\n<p>The U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Data from its final analysis of the trial disclosed on Tuesday includes an additional 1,000 people.</p>\n<p>Nobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients.</p>\n<p>The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.</p>\n<p>\"It's a stunning outcome,\" Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.</p>\n<p>\"We're talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically,\" Dolsten said.</p>\n<p>Pfizer also released early data from a second study suggesting that the treatment reduced hospitalizations by around 70% in a smaller trial of standard-risk adults, including some higher-risk vaccinated people.</p>\n<p>Pfizer said those results showed a positive trend, but were not statistically significant. They are following the results and plan to release data from the final 20% of participants in the 1,100-patient trial. The trial did not show that the drug alleviated symptoms of COVID-19 in that population.</p>\n<p>Dolsten said he expects authorization for use in high-risk individuals from the U.S. Food and Drug Administration and other regulatory agencies soon. He does not believe an FDA advisory panel meeting will be needed.</p>\n<p>\"We're in very advanced regulatory dialogues with both Europe and the UK, and we have dialogues with most of the major regulatory agencies globally,\" Dolsten said.</p>\n<p><b>'VERY EXCITING RESULTS'</b></p>\n<p>Pfizer submitted data to the FDA last month, asking for emergency use authorization (EUA) of the drug.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/04e1175e6a0c8ba936538fabc8038071\" tg-width=\"960\" tg-height=\"640\" width=\"100%\" height=\"auto\"><span>Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS</span></p>\n<p>\"These are very exciting results,\" said Dr. Paul Sax, a professor at Harvard Medical School.</p>\n<p>Sax said the FDA should try to accelerate the authorization process as much as possible, noting there are very limited treatment options for high-risk people outside of the hospital.</p>\n<p>There are currently no oral antiviral treatments for COVID-9 authorized in the United States.</p>\n<p>Analysts on average forecast 2022 revenue of more than $24 billion from the pill, which would more than make up for any decline in vaccine sales after 2021.</p>\n<p>Rival Merck &amp; Co&nbsp;has asked for an EUA for its antiviral pill molnupiravir. But that drug only reduced hospitalizations and deaths in its clinical trial of high-risk patients by around 30%.</p>\n<p>Some scientists have also raised safety concerns about the potential for birth defects from the Merck drug, as well as worries that it could cause the virus to mutate.</p>\n<p>Pfizer's treatment works differently. It is part of a class of drugs called protease inhibitors currently used to treat HIV, hepatitis C and other viruses.</p>\n<p>Recent laboratory testing showed that activity against the protease of the Omicron variant is as \"good as basically any SARS-COV-2 variant of concern,\" Dolsten said.</p>\n<p>The company has said it can have 180,000 treatment courses ready to ship this year and plans to produce at least 80 million more in 2022.</p>\n<p>Dolsten said Pfizer is looking to expand that output further as new variants, like the newly-discovered Omicron, could push the need for antivirals substantially higher. Current vaccines appear to be less effective at preventing infection with Omicron.</p>\n<p>Pfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech , has agreed to allow generic manufacturers to supply versions of the drug to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). However, Dolsten said that for next year he expects the drug will be mainly produced by Pfizer.</p>\n<p>The MPP told Reuters in a statement, that it will be \"well into next year\" before pills produced by generic manufacturers under its licenses will be ready for use.</p>\n<p>The U.S. government has already secured 10 million courses of the Pfizer treatment for $5.29 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer says COVID-19 pill near 90% protective against hospitalization, death</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer says COVID-19 pill near 90% protective against hospitalization, death\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-15 06:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Dec 14 (Reuters) - Pfizer Inc&nbsp;on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.</p>\n<p>The U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Data from its final analysis of the trial disclosed on Tuesday includes an additional 1,000 people.</p>\n<p>Nobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients.</p>\n<p>The Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.</p>\n<p>\"It's a stunning outcome,\" Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.</p>\n<p>\"We're talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically,\" Dolsten said.</p>\n<p>Pfizer also released early data from a second study suggesting that the treatment reduced hospitalizations by around 70% in a smaller trial of standard-risk adults, including some higher-risk vaccinated people.</p>\n<p>Pfizer said those results showed a positive trend, but were not statistically significant. They are following the results and plan to release data from the final 20% of participants in the 1,100-patient trial. The trial did not show that the drug alleviated symptoms of COVID-19 in that population.</p>\n<p>Dolsten said he expects authorization for use in high-risk individuals from the U.S. Food and Drug Administration and other regulatory agencies soon. He does not believe an FDA advisory panel meeting will be needed.</p>\n<p>\"We're in very advanced regulatory dialogues with both Europe and the UK, and we have dialogues with most of the major regulatory agencies globally,\" Dolsten said.</p>\n<p><b>'VERY EXCITING RESULTS'</b></p>\n<p>Pfizer submitted data to the FDA last month, asking for emergency use authorization (EUA) of the drug.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/04e1175e6a0c8ba936538fabc8038071\" tg-width=\"960\" tg-height=\"640\" width=\"100%\" height=\"auto\"><span>Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS</span></p>\n<p>\"These are very exciting results,\" said Dr. Paul Sax, a professor at Harvard Medical School.</p>\n<p>Sax said the FDA should try to accelerate the authorization process as much as possible, noting there are very limited treatment options for high-risk people outside of the hospital.</p>\n<p>There are currently no oral antiviral treatments for COVID-9 authorized in the United States.</p>\n<p>Analysts on average forecast 2022 revenue of more than $24 billion from the pill, which would more than make up for any decline in vaccine sales after 2021.</p>\n<p>Rival Merck &amp; Co&nbsp;has asked for an EUA for its antiviral pill molnupiravir. But that drug only reduced hospitalizations and deaths in its clinical trial of high-risk patients by around 30%.</p>\n<p>Some scientists have also raised safety concerns about the potential for birth defects from the Merck drug, as well as worries that it could cause the virus to mutate.</p>\n<p>Pfizer's treatment works differently. It is part of a class of drugs called protease inhibitors currently used to treat HIV, hepatitis C and other viruses.</p>\n<p>Recent laboratory testing showed that activity against the protease of the Omicron variant is as \"good as basically any SARS-COV-2 variant of concern,\" Dolsten said.</p>\n<p>The company has said it can have 180,000 treatment courses ready to ship this year and plans to produce at least 80 million more in 2022.</p>\n<p>Dolsten said Pfizer is looking to expand that output further as new variants, like the newly-discovered Omicron, could push the need for antivirals substantially higher. Current vaccines appear to be less effective at preventing infection with Omicron.</p>\n<p>Pfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech , has agreed to allow generic manufacturers to supply versions of the drug to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). However, Dolsten said that for next year he expects the drug will be mainly produced by Pfizer.</p>\n<p>The MPP told Reuters in a statement, that it will be \"well into next year\" before pills produced by generic manufacturers under its licenses will be ready for use.</p>\n<p>The U.S. government has already secured 10 million courses of the Pfizer treatment for $5.29 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","PFE":"辉瑞","BK4550":"红杉资本持仓","BK4007":"制药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191937155","content_text":"NEW YORK, Dec 14 (Reuters) - Pfizer Inc on Tuesday said its antiviral COVID-19 pill showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus.\nThe U.S. drugmaker last month said the oral medicine was around 89% effective in preventing hospitalizations or deaths when compared to placebo, based on interim results in around 1,200 people. Data from its final analysis of the trial disclosed on Tuesday includes an additional 1,000 people.\nNobody in the trial who received the Pfizer treatment died, compared with 12 deaths among placebo recipients.\nThe Pfizer pills are taken with the older antiviral ritonavir every 12 hours for five days beginning shortly after onset of symptoms. If authorized, the treatment will be sold as Paxlovid.\n\"It's a stunning outcome,\" Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.\n\"We're talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically,\" Dolsten said.\nPfizer also released early data from a second study suggesting that the treatment reduced hospitalizations by around 70% in a smaller trial of standard-risk adults, including some higher-risk vaccinated people.\nPfizer said those results showed a positive trend, but were not statistically significant. They are following the results and plan to release data from the final 20% of participants in the 1,100-patient trial. The trial did not show that the drug alleviated symptoms of COVID-19 in that population.\nDolsten said he expects authorization for use in high-risk individuals from the U.S. Food and Drug Administration and other regulatory agencies soon. He does not believe an FDA advisory panel meeting will be needed.\n\"We're in very advanced regulatory dialogues with both Europe and the UK, and we have dialogues with most of the major regulatory agencies globally,\" Dolsten said.\n'VERY EXCITING RESULTS'\nPfizer submitted data to the FDA last month, asking for emergency use authorization (EUA) of the drug.\nPaxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS\n\"These are very exciting results,\" said Dr. Paul Sax, a professor at Harvard Medical School.\nSax said the FDA should try to accelerate the authorization process as much as possible, noting there are very limited treatment options for high-risk people outside of the hospital.\nThere are currently no oral antiviral treatments for COVID-9 authorized in the United States.\nAnalysts on average forecast 2022 revenue of more than $24 billion from the pill, which would more than make up for any decline in vaccine sales after 2021.\nRival Merck & Co has asked for an EUA for its antiviral pill molnupiravir. But that drug only reduced hospitalizations and deaths in its clinical trial of high-risk patients by around 30%.\nSome scientists have also raised safety concerns about the potential for birth defects from the Merck drug, as well as worries that it could cause the virus to mutate.\nPfizer's treatment works differently. It is part of a class of drugs called protease inhibitors currently used to treat HIV, hepatitis C and other viruses.\nRecent laboratory testing showed that activity against the protease of the Omicron variant is as \"good as basically any SARS-COV-2 variant of concern,\" Dolsten said.\nThe company has said it can have 180,000 treatment courses ready to ship this year and plans to produce at least 80 million more in 2022.\nDolsten said Pfizer is looking to expand that output further as new variants, like the newly-discovered Omicron, could push the need for antivirals substantially higher. Current vaccines appear to be less effective at preventing infection with Omicron.\nPfizer, which makes one of the leading COVID-19 vaccines with German partner BioNTech , has agreed to allow generic manufacturers to supply versions of the drug to 95 low- and middle-income countries through a licensing agreement with international public health group Medicines Patent Pool (MPP). However, Dolsten said that for next year he expects the drug will be mainly produced by Pfizer.\nThe MPP told Reuters in a statement, that it will be \"well into next year\" before pills produced by generic manufacturers under its licenses will be ready for use.\nThe U.S. government has already secured 10 million courses of the Pfizer treatment for $5.29 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1072,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604411980,"gmtCreate":1639438187676,"gmtModify":1639438272899,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"🤦‍♂️","listText":"🤦‍♂️","text":"🤦‍♂️","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604411980","repostId":"1180743412","repostType":4,"repost":{"id":"1180743412","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639408228,"share":"https://www.laohu8.com/m/news/1180743412?lang=&edition=full","pubTime":"2021-12-13 23:10","market":"us","language":"en","title":"Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180743412","media":"Tiger Newspress","summary":"Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.","content":"<p>Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.<img src=\"https://static.tigerbbs.com/8c494e3841010c65a07f05aaacf0d443\" tg-width=\"772\" tg-height=\"573\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 23:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.<img src=\"https://static.tigerbbs.com/8c494e3841010c65a07f05aaacf0d443\" tg-width=\"772\" tg-height=\"573\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PHUN":"Phunware, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1180743412","content_text":"Trump stocks slid sharply in morning trading ,with DWAC and Phunware falling over 5%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":950,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603216892,"gmtCreate":1638412417840,"gmtModify":1638413977936,"author":{"id":"3573003064152790","authorId":"3573003064152790","name":"EthanOng","avatar":"https://static.tigerbbs.com/0a1dbd6c23a4169340f08265e0a807f9","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573003064152790","authorIdStr":"3573003064152790"},"themes":[],"htmlText":"Tinder is an app that’s full of scammer accounts. What’s the point?","listText":"Tinder is an app that’s full of scammer accounts. What’s the point?","text":"Tinder is an app that’s full of scammer accounts. What’s the point?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/603216892","repostId":"2188564633","repostType":4,"isVote":1,"tweetType":1,"viewCount":1017,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}